Landscape → Immunology

Atopic Dermatitis Clinical Trial Landscape

Data updated: May 20, 2026

812 clinical trials tracked since 2008

Atopic dermatitis (AD), also known as eczema, is a chronic inflammatory skin condition characterized by itchy, inflamed skin. It commonly begins in childhood but can affect individuals of all ages. The clinical trial landscape for atopic dermatitis immunology is active, with 808 trials registered since 2008, including 168 currently active trials. Activity is distributed across all phases, with a notable concentration in Phase 2 trials (66 active trials out of 376 total). Phase 1 trials account for 38 active trials out of 197 total, Phase 3 trials account for 50 active trials out of 206 total, and Phase 4 trials account for 20 active trials out of 81 total. Several industry sponsors are actively involved in atopic dermatitis clinical trials, with Pfizer, AbbVie, and Guangdong Hengrui Pharmaceutical Co., Ltd each sponsoring 6 active trials. Eli Lilly and Keymed Biosciences Co.Ltd are also prominent sponsors, each with 5 active trials.

169 active

812 total (since 2008)

Phase 1 Active

198 total

Phase 2 Active

378 total

Phase 3 Active

206 total

Phase 4 Active

82 total

Top Industry Sponsors

Sorted by active Active Done Failed

Pfizer 6 30 3

AbbVie 6 9 3

Guangdong Hengrui Pharmaceutical Co., Ltd 6 0 0

Eli Lilly 5 19 5

Keymed Biosciences Co.Ltd 5 9 0

+ 10 more sponsors — see full table below

Featured Phase 3 Trials

NCT06389136 RECRUITING

A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab

AbbVie n=200

NCT06807268 RECRUITING

A Study of the Medicine Called Abrocitinib in Children 6 to Less Than 12 Years of Age With Moderate-to-Severe Eczema

Pfizer n=150

NCT05882877 ACTIVE NOT RECRUITING

A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)

Amgen n=2,621

NCT03952559 ACTIVE NOT RECRUITING

A Study of Baricitinib (LY3009104) in Children and Adolescents With Atopic Dermatitis

Eli Lilly and Company n=516

NCT06526182 ACTIVE NOT RECRUITING

A Study of Lebrikizumab Treatment in Adults and Adolescents With Moderate-to-Severe Atopic Dermatitis

Almirall, S.A. n=520

+ 201 more Phase 3 trials — see full database below

Atopic Dermatitis — Trials Started by Year (last 10 years)

2016

2017

2018

2019

2020

2021

2022

2023

2024

2025

2026

TheraRadar.com

Full Trial Database

Complete sponsor table, every trial across all phases, plus competitive analytics. Sortable, filterable, exportable for Pro users.

Top Sponsors (all-time)

Pfizer

AbbVie

Guangdong Hengrui Pharmaceutical Co., Ltd

Eli Lilly

Keymed Biosciences Co.Ltd

Jiangsu vcare pharmaceutical technology co., LTD

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

Shanghai Mabgeek Biotech.Co.Ltd

Almirall, S.A.

Akeso

Active Trials by Phase

Phase 1

Phase 2

Phase 3

Phase 4

Enrollment Size Distribution

1-50

249

51-200

304

201-500

165

501-1k

1k+

All Industry Sponsors

Sorted by active Active Done Failed

Pfizer 6 30 3

AbbVie 6 9 3

Guangdong Hengrui Pharmaceutical Co., Ltd 6 0 0

Eli Lilly 5 19 5

Keymed Biosciences Co.Ltd 5 9 0

Jiangsu vcare pharmaceutical technology co., LTD 4 5 0

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. 4 3 0

Shanghai Mabgeek Biotech.Co.Ltd 4 0 0

Almirall, S.A. 3 4 0

Akeso 3 3 0

Qilu Pharmaceutical Co., Ltd. 3 3 0

Innovent Biologics (Suzhou) Co. Ltd. 3 1 0

Apogee Therapeutics, Inc. 3 0 0

Regeneron 2 19 4

Novartis 2 6 2

NCT06389136 RECRUITING

A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab

AbbVie n=200

NCT05735483 ENROLLING BY INVITATION

A Study to Assess the Long-Term Safety and Efficacy of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis

Eli Lilly and Company n=310

NCT06807268 RECRUITING

A Study of the Medicine Called Abrocitinib in Children 6 to Less Than 12 Years of Age With Moderate-to-Severe Eczema

Pfizer n=150

NCT05882877 ACTIVE NOT RECRUITING

A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)

Amgen n=2,621

NCT03952559 ACTIVE NOT RECRUITING

A Study of Baricitinib (LY3009104) in Children and Adolescents With Atopic Dermatitis

Eli Lilly and Company n=516

NCT07542483 NOT YET RECRUITING

A Study of Lebrikizumab in Adults With Nummular Eczema

Almirall, S.A. n=270

NCT06526182 ACTIVE NOT RECRUITING

A Study of Lebrikizumab Treatment in Adults and Adolescents With Moderate-to-Severe Atopic Dermatitis

Almirall, S.A. n=520

NCT07540442 NOT YET RECRUITING

A Phase III Study of MG-K10 in Adolescents With Moderate-to-Severe Atopic Dermatitis

Shanghai Mabgeek Biotech.Co.Ltd n=180

NCT06552520 ACTIVE NOT RECRUITING

To Evaluate the Phase III Clinical Trial of TQH2722 Injection in the Treatment of Moderate to Severe Atopic Dermatitis

Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. n=500

NCT07265479 RECRUITING

A Study to Investigate Safety and Efficacy of Tapinarof Cream, 1% in Participants Ages 3 Months to < 24 Months With Atopic Dermatitis

Organon and Co n=180

NCT07309055 RECRUITING

A Study of SHR-1819 Injection in Adolescents With Severe Atopic Dermatitis

Guangdong Hengrui Pharmaceutical Co., Ltd n=201

NCT06807281 RECRUITING

A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema

Pfizer n=500

NCT06461897 RECRUITING

A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis

AbbVie n=675

NCT06311682 RECRUITING

A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic Dermatitis

LEO Pharma n=195

NCT07479615 NOT YET RECRUITING

A Study to Evaluate the Efficacy and Safety of MG-K10 in Participants Who Have Atopic Dermatitis

Shanghai Mabgeek Biotech.Co.Ltd n=498

NCT06701331 ACTIVE NOT RECRUITING

Safety and Efficacy of Upadacitinib in Combination With Topical Corticosteroids in Children From 2 to Less Than 12 Years of Age in Japan With Moderate to Severe Atopic Dermatitis

AbbVie n=99

NCT07377838 NOT YET RECRUITING

Study of ADSTEM Injection for Patients With Moderate to Severe Subacute and Chronic Atopic Dermatitis

EHL Bio Co., Ltd. n=286

NCT07386743 NOT YET RECRUITING

A Phase III Study of GS101 Injection to Dupixent®

Jiangsu Genscend Biopharmaceutical Co., Ltd n=572

NCT07370909 NOT YET RECRUITING

Evaluation of the Efficacy and Safety of Oral LW402 Tablets for the Treatment of Patients With Moderate-to-Severe Atopic Dermatitis

Shanghai Longwood Biopharmaceuticals Co., Ltd. n=480

NCT05559359 ACTIVE NOT RECRUITING

A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis

Eli Lilly and Company n=367

NCT05526222 ACTIVE NOT RECRUITING

A Phase III Study of Jaktinib in Adults With Moderate and Severe Atopic Dermatitis

Suzhou Zelgen Biopharmaceuticals Co.,Ltd n=443

NCT03568318 ACTIVE NOT RECRUITING

A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis

AbbVie n=1,533

NCT06832618 RECRUITING

A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children and Adolescents (6 to <18 Years Old) With Moderate Atopic Dermatitis

Incyte Corporation n=240

NCT07042126 RECRUITING

Evaluation of 611 in Chinese Adolescents With Moderate to Severe Atopic Dermatitis

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. n=180

NCT06280716 ACTIVE NOT RECRUITING

A Study of Lebrikizumab (LY3650150) With/Without Topical Corticosteroid Treatment in Participants With Moderate-to-Severe Atopic Dermatitis

Eli Lilly and Company n=301

NCT06495229 ACTIVE NOT RECRUITING

Study of CM310 in Adolescent Subjects With Atopic Dermatis

Keymed Biosciences Co.Ltd n=180

NCT06570889 RECRUITING

VItamin D in pregnanCy for prevenTion Of eaRlY Childhood Asthma

Professor Klaus Bønnelykke n=2,000

NCT06560255 RECRUITING

Fish Oil in pREgnancY for Personalized Prevention of Early Childhood Asthma

Professor Klaus Bønnelykke n=2,000

NCT07184645 NOT YET RECRUITING

A Phase 3 Trial of OPA-15406 Foam in Children and Infants With Atopic Dermatitis

Otsuka Pharmaceutical Co., Ltd. n=198

NCT07180511 ENROLLING BY INVITATION

A Phase III Clinical Study of QY201 Tablet in Subjects With Moderate to Severe Atopic Dermatitis.

E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd. n=460

NCT07173478 NOT YET RECRUITING

A Phase 3 Trial to Demonstrate the Superiority of 1% OPA-15406 Foam to the Vehicle in Adult Patients With Atopic Dermatitis

Otsuka Pharmaceutical Co., Ltd. n=156

NCT06468956 ACTIVE NOT RECRUITING

Efficacy and Safety Study of SHR-1819 Injection in Adult Patients With Severe Atopic Dermatitis

Guangdong Hengrui Pharmaceutical Co., Ltd n=652

NCT07162896 NOT YET RECRUITING

Crisaborole 2% Versus Tacrolimus 0.1% in Children With Mild to Moderate Atopic Dermatitis

Shalamar Institute of Health Sciences n=66

NCT06775860 RECRUITING

ICP-332 in Subjects With Moderate to Severe Atopic Dermatitis

Beijing InnoCare Pharma Tech Co., Ltd. n=552

NCT06239311 RECRUITING

Efficacy and Safety of Methotrexate Versus Placebo in Adults With Atopic Dermatitis.

medac GmbH n=277

NCT06880276 RECRUITING

Efficacy and Safety Study of QLM3003 Ointment in Participants With Mild or Moderate Atopic Dermatitis

Qilu Pharmaceutical Co., Ltd. n=360

NCT07106372 NOT YET RECRUITING

A Study of Stapokibatrt in Children Subjects With Atopic Dermatitis

Keymed Biosciences Co.Ltd n=240

NCT06554847 ACTIVE NOT RECRUITING

Evaluation of 611 in Combination With Topical Corticosteroid in Participants With Moderate to Severe Atopic Dermatitis

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. n=400

NCT02612454 ACTIVE NOT RECRUITING

Study to Assess the Long-term Safety of Dupilumab Administered in Participants ≥6 Months to <18 Years of Age With Atopic Dermatitis (AD)

Regeneron Pharmaceuticals n=880

NCT06587685 RECRUITING

A Study to Assess the Efficacy and Safety of PG-011 Gel in Adolescents and Adults With Atopic Dermatitis

Prime Gene Therapeutics Co., Ltd. n=472

NCT06956196 NOT YET RECRUITING

Study of Stapokibatrt in Children Subjects With Atopic Dermatitis

Keymed Biosciences Co.Ltd n=240

NCT05990725 ACTIVE NOT RECRUITING

Effectiveness and Safety of Lebrikizumab Treatment in Adults and Adolescents With Moderate-to-Severe Atopic Dermatitis

Almirall, S.A. n=240

NCT06884891 NOT YET RECRUITING

A Phase Ⅲ Comparative Study of QL2108 to Dupixent®

Qilu Pharmaceutical Co., Ltd. n=520

NCT06850311 RECRUITING

Herbal Ointment in Treating Atopic Dermatitis Topically

En Chu Kong Hospital n=66

NCT06723080 RECRUITING

Phase III Clinical Study of VC005 Tablets in Adult Patients With Moderate to Severe Atopic Dermatitis

Jiangsu vcare pharmaceutical technology co., LTD n=480

NCT06767540 NOT YET RECRUITING

A Clinical Study of AK120 in Adolescents With Moderate-to-severe Atopic Dermatitis

Akeso n=198

NCT03989206 ACTIVE NOT RECRUITING

Long-term Safety and Efficacy of Nemolizumab With Moderate-to-severe Atopic Dermatitis

Galderma R&D n=1,700

NCT03667651 ACTIVE NOT RECRUITING

The PEBBLES Study - Testing a Strategy for Preventing Eczema and Food Allergy in High Risk Infants

University of Melbourne n=760

NCT07592585 NOT YET RECRUITING

Phase III Clinical Study of VC005 in Adult and Adolescents With Mild to Moderate Atopic Dermatitis

Jiangsu vcare pharmaceutical technology co., LTD n=360

NCT05355818 COMPLETED

Efficacy and Safety of Delgocitinib Cream in Adolescents 12-17 Years of Age With Moderate to Severe Chronic Hand Eczema

LEO Pharma n=98

NCT06277245 COMPLETED

A Phase 3 Study of LNK01001 Capsule in Subjects With Moderate to Severe Atopic Dermatitis.

Lynk Pharmaceuticals Co., Ltd n=356

NCT06477835 COMPLETED

A Study to Evaluate the Efficacy and Safety of SIM0718 in Adult and Adolescent Patients With Moderate to Severe Atopic Dermatitis

Simcere Pharmaceutical Co., Ltd n=259

NCT06224192 COMPLETED

A Study With Self-administered Rocatinlimab in Adolescent and Adult Participants With Moderate-to-severe Atopic Dermatitis

Amgen n=151

NCT05372419 COMPLETED

A Study of (LY3650150) Lebrikizumab to Assess the Safety and Efficacy of Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis and Skin of Color

Eli Lilly and Company n=90

NCT05369403 COMPLETED

A Study of Lebrikizumab (LY3650150) in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis Previously Treated With Dupilumab

Eli Lilly and Company n=86

NCT05378698 TERMINATED

Effects of Tralokinumab in the Skin: an Immunologic and Molecular Investigation

University of Zurich n=24

NCT05704738 COMPLETED

A Study to Evaluate Rocatinlimab (AMG 451) in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)

Amgen n=532

NCT03422822 COMPLETED

Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis

Pfizer n=3,166

NCT06173284 COMPLETED

Evaluation of 611(Recombinant Humanized Anti-interleukin-4 Receptor Alpha IgG4 Monoclonal Antibody) in Chinese Adults With Moderate to Severe Atopic Dermatitis

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. n=519

NCT05958407 COMPLETED

A 32-week Trial to Evaluate the Efficacy and Safety of Tralokinumab in Subjects With Moderate-to-severe Atopic Hand Eczema Who Are Candidates for Systemic Therapy

LEO Pharma n=235

NCT04804605 COMPLETED

Open Label Extension Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis

Arcutis Biotherapeutics, Inc. n=1,220

NCT04845620 COMPLETED

Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis (Integument-PED)

Arcutis Biotherapeutics, Inc. n=652

NCT05633355 COMPLETED

A Study to Assess the Safety, Tolerability, and Efficacy of Rocatinlimab in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)

Amgen n=187

NCT03607422 COMPLETED

A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Measure Up 2)

AbbVie n=912

NCT05724199 COMPLETED

A Study Assessing Rocatinlimab in Combination With Topical Corticosteroid and/or Topical Calcineurin Inhibitors in Adult Participants With Moderate-to-severe Atopic Dermatitis (AD)

Amgen n=746

NCT05398445 COMPLETED

A Study Evaluating Rocatinlimab in Moderate-to-severe Atopic Dermatitis (ROCKET-IGNITE)

Amgen n=769

NCT04686955 COMPLETED

The Efficacy of Patients With Moderate to Severe Atopic Dermatitis Treated With Chinese Herbal Medicine

Taipei Veterans General Hospital, Taiwan n=19

NCT04392154 COMPLETED

Long-term Safety and Efficacy Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis (ADjoin)

Eli Lilly and Company n=1,153

NCT05899816 COMPLETED

A Study Assessing Rocatinlimab on Vaccine Antibody Response in Moderate-to-severe Atopic Dermatitis (AD) (ROCKET - VOYAGER)

Amgen n=221

NCT06238817 COMPLETED

A Study to Evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis

Incyte Corporation n=241

NCT03569293 COMPLETED

Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema)

AbbVie n=912

NCT06277765 COMPLETED

Study of CM310 Injection in Adolescent Subjects With Atopic Dermatis

Keymed Biosciences Co.Ltd n=180

NCT00809172 COMPLETED

Study of Methotrexate Efficacy Versus Cyclosporine in Moderate to Severe Atopic Dermatitis Patients

Hospices Civils de Lyon n=100

NCT06004050 COMPLETED

A Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Delgocitinib Cream in Chinese Adults and Adolescents With Moderate to Severe Chronic Hand Eczema

LEO Pharma n=362

NCT07185282 COMPLETED

A Phase 3 Study of MH004 Ointment in Patients With Mild to Moderate Atopic Dermatitis

Minghui Pharmaceutical (Hangzhou) Ltd n=375

NCT04678882 COMPLETED

Dupilumab in Japanese Patients With Atopic Dermatitis

Sanofi n=62

NCT05014568 COMPLETED

Tapinarof for the Treatment of Atopic Dermatitis in Children and Adults

Organon and Co n=407

NCT05032859 COMPLETED

Tapinarof for the Treatment of Atopic Dermatitis in Children and Adults (DMVT-505-3102)

Organon and Co n=406

NCT06631170 COMPLETED

Efficacy and Safety of Roflumilast Cream in Subjects With Atopic Dermatitis

Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. n=354

NCT05667623 COMPLETED

To Demonstrate the Superiority of IMP (1% OPA-15406 Ointment) to the Vehicle in Adult Patients With AD

Otsuka Beijing Research Institute n=270

NCT05142774 COMPLETED

Long Term Extension Study of Tapinarof Cream, 1% for Subjects With Atopic Dermatitis

Organon and Co n=728

NCT06444165 COMPLETED

Lebrikizumab Pen Ease of Use in Participants With Atopic Dermatitis

Eli Lilly and Company n=55

NCT05456529 COMPLETED

Study of Ruxolitinib Cream in Adolescents With Atopic Dermatitis

Incyte Corporation n=103

NCT05149313 COMPLETED

A Study of Lebrikizumab in Combination With Topical Corticosteroids in Patients With Atopic Dermatitis (AD) That Are Not Adequately Controlled With or Are Non-eligible for Cyclosporine

Almirall, S.A. n=331

NCT05259722 COMPLETED

A 24 Week Trial to Compare the Efficacy and Safety of Delgocitinib Cream 20 mg/g Twice-daily With Alitretinoin Capsules Once-daily in Adult Participants With Severe Chronic Hand Eczema

LEO Pharma n=513

NCT05732454 TERMINATED

A Study to Learn About the Study Medicine Etrasimod in Adults With Moderate to Severe Atopic Dermatitis (AD) Who Have Already Tried Treatments Taken by Mouth or by Injection

Pfizer n=58

NCT05916365 COMPLETED

Long-term Safety and Efficacy of Lebrikizumab in Adult and Adolescent Participant With Moderate-to-Severe Atopic Dermatitis

Almirall, S.A. n=174

NCT04872101 COMPLETED

Efficacy and Safety of Delgocitinib Cream in Adults With Moderate to Severe Chronic Hand Eczema (DELTA 2)

LEO Pharma n=473

NCT04871711 COMPLETED

Efficacy and Safety of Delgocitinib Cream in Adults With Moderate to Severe Chronic Hand Eczema

LEO Pharma n=487

NCT04949841 COMPLETED

Open-label Multi-site Extension Trial in Subjects Who Completed the DELTA 1 or DELTA 2 Trials

LEO Pharma n=801

NCT05651711 COMPLETED

A Study Assessing Rocatinlimab (AMG 451) Monotherapy in Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-Horizon)

Amgen n=726

NCT05372653 COMPLETED

A Long-term Trial of OPA-15406 in Infants With Atopic Dermatitis

Otsuka Pharmaceutical Co., Ltd. n=41

NCT04921969 COMPLETED

A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children With Atopic Dermatitis (TRuE-AD3)

Incyte Corporation n=330

NCT05650320 COMPLETED

To Demonstrate the Superiority of IMP (0.3% and 1% OPA-15406 Ointment) Versus the Vehicle in Pediatric Patients with AD

Otsuka Beijing Research Institute n=240

NCT03587805 COMPLETED

Long-term Extension Trial in Subjects With Atopic Dermatitis Who Participated in Previous Tralokinumab Trials - ECZTEND

LEO Pharma n=1,672

NCT03761537 COMPLETED

Tralokinumab in Combination With Topical Corticosteroids in Subjects With Severe Atopic Dermatitis - ECZTRA 7

LEO Pharma n=277

NCT04587453 COMPLETED

Tralokinumab in Combination With Topical Corticosteroids in Japanese Subjects With Moderate-to-severe Atopic Dermatitis

LEO Pharma n=106

NCT03131648 COMPLETED

Tralokinumab Monotherapy for Moderate to Severe Atopic Dermatitis - ECZTRA 1 (ECZema TRAlokinumab Trial no. 1)

LEO Pharma n=802

NCT03160885 COMPLETED

Tralokinumab Monotherapy for Moderate to Severe Atopic Dermatitis - ECZTRA 2 (ECZema TRAlokinumab Trial no. 2)

LEO Pharma n=794

NCT05194540 COMPLETED

Efficacy and Safety of Tralokinumab Administered by an Autoinjector in Adults and Adolescents With Moderate to Severe Atopic Dermatitis (INJECZTRA)

LEO Pharma n=136

NCT03526861 COMPLETED

Tralokinumab Monotherapy for Adolescent Subjects With Moderate to Severe Atopic Dermatitis - ECZTRA 6 (ECZema TRAlokinumab Trial no. 6).

LEO Pharma n=301

NCT03363854 COMPLETED

Tralokinumab in Combination With Topical Corticosteroids for Moderate to Severe Atopic Dermatitis - ECZTRA 3

LEO Pharma n=380

NCT03395132 TERMINATED

Efficacy and Safety of Fucicort® Lipid Cream Compared to Combination Treatment With Fucidin® Cream Followed by Betamethasone (Lianbang Beisong®) Cream and Fucicort® Lipid Cream Vehicle in Clinically Infected Atopic Dermatitis/Eczema

LEO Pharma n=68

NCT01906853 COMPLETED

Melbourne Infant Study - Bacille Calmette Guérin (BCG) for Allergy & Infection Reduction

Murdoch Childrens Research Institute n=1,272

NCT05601882 COMPLETED

A Study to Evaluate Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis

AbbVie n=920

NCT04195698 COMPLETED

Open-Label Extension Study of Upadacitinib in Adult Participants With Moderate to Severe Atopic Dermatitis

AbbVie n=475

NCT05265923 COMPLETED

A Study of CM310 in Patients With Moderate-to-Severe Atopic Dermatitis

Keymed Biosciences Co.Ltd n=500

NCT05375929 COMPLETED

A Study to Learn About Abrocitinib Tablets in People With Atopic Dermatitis in India

Pfizer n=200

NCT04773587 COMPLETED

Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis

Arcutis Biotherapeutics, Inc. n=654

NCT04773600 COMPLETED

Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis (INTEGUMENT-II)

Arcutis Biotherapeutics, Inc. n=683

NCT06390722 WITHDRAWN

A Study to Assess the Effect of Upadacitinib in Atopic Dermatitis-induced Sleep Disturbance in Adults With Moderate to Severe Atopic Dermatitis

AbbVie

NCT03334435 COMPLETED

A Study of Long-term Baricitinib (LY3009104) Therapy in Atopic Dermatitis

Eli Lilly and Company n=1,645

NCT05608343 COMPLETED

This Study is to Assess the Efficacy of Difamilast Ointment in Mild to Moderate Atopic Dermatitis(AD)

Acrotech Biopharma Inc. n=153

NCT03985943 COMPLETED

Efficacy and Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis

Galderma R&D n=941

NCT03989349 COMPLETED

Efficacy & Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis

Galderma R&D n=787

NCT05571943 COMPLETED

A Open-label Study to Assess the Long-term Safety of Difamilast Ointment 1% in Mild to Moderate Atopic Dermatitis

Acrotech Biopharma Inc. n=542

NCT01916980 COMPLETED

Efficacy and Safety Study of Desloratadine (MK-4117) in Japanese Participants With Eczema/Dermatitis and Dermal Pruritus (MK-4117-202)

Organon and Co n=94

NCT03428100 COMPLETED

A Long-term Study of Baricitinib (LY3009104) With Topical Corticosteroids in Adults With Moderate to Severe Atopic Dermatitis That Are Not Controlled With Cyclosporine or for Those Who Cannot Take Oral Cyclosporine Because it is Not Medically Advisable

Eli Lilly and Company n=463

NCT04140695 TERMINATED

Evaluating the Effects of Tradipitant vs. Placebo in Atopic Dermatitis (EPIONE2)

Vanda Pharmaceuticals n=87

NCT03568331 COMPLETED

Evaluating the Effects of Tradipitant vs. Placebo in Atopic Dermatitis (EPIONE)

Vanda Pharmaceuticals n=375

NCT06361992 COMPLETED

Efficacy and Safety of Blue Cap for the Treatment of Atopic Dermatitis in Children

Catalysis SL n=58

NCT03738397 COMPLETED

A Study to Compare Safety and Efficacy of Upadacitinib to Dupilumab in Adult Participants With Moderate to Severe Atopic Dermatitis

AbbVie n=673

NCT05387707 TERMINATED

Study to Evaluate the Efficacy and Safety of Oral Difelikefalin as Adjunct Therapy to a Topical Corticosteroid for Moderate to Severe Pruritus in Subjects With Atopic Dermatitis

Cara Therapeutics, Inc. n=287

NCT03912259 COMPLETED

Evaluation of Dupilumab in Chinese Adult Patients With Moderate to Severe Atopic Dermatitis

Sanofi n=165

NCT05003453 COMPLETED

The Effectiveness of a Topical Palmitoylethanolamide (PEA) Formulation (Levagen+) for Reducing Symptoms of Eczema

RDC Clinical Pty Ltd n=72

NCT01949311 COMPLETED

Open-label Study of Dupilumab in Patients With Atopic Dermatitis

Regeneron Pharmaceuticals n=2,733

NCT04626297 COMPLETED

A Study of Lebrikizumab (LY3650150) on Vaccine Response in Adults With Atopic Dermatitis (ADopt-VA)

Eli Lilly and Company n=254

NCT03745638 COMPLETED

Topical Ruxolitinib Evaluation in Atopic Dermatitis Study 1 (TRuE AD1) - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis

Incyte Corporation n=631

NCT03745651 COMPLETED

TRuE AD2 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis

Incyte Corporation n=618

NCT05056779 WITHDRAWN

Efficacy and Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis With Inadequate Response to or for Whom Cyclosporine A is Not Medically Advisable

Galderma R&D

NCT04760314 COMPLETED

A Study of Lebrikizumab (LY3650150) in Combination With Topical Corticosteroids in Japanese Participants With Moderate-to-Severe Atopic Dermatitis

Eli Lilly and Company n=286

NCT04875169 COMPLETED

Evaluate Efficacy and Safety of Oral SHR0302 in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis

Reistone Biopharma Company Limited n=336

NCT04178967 COMPLETED

Evaluation of the Efficacy and Safety of Lebrikizumab (LY3650150) in Moderate to Severe Atopic Dermatitis

Eli Lilly and Company n=445

NCT03058783 COMPLETED

Efficacy and Safety of IDP-124 Lotion for the Treatment of Moderate to Severe Atopic Dermatitis in Pediatric and Adult Subjects

Bausch Health Americas, Inc. n=328

NCT03002571 COMPLETED

Efficacy and Safety of IDP-124 Lotion for the Treatment of Moderate to Severe Atopic Dermatitis in Pediatric and Adult Subjects (301)

Bausch Health Americas, Inc. n=338

NCT05614817 WITHDRAWN

CBP-201 in Adolescent and Adult Patients With Moderate-to-severe Atopic Dermatitis

Connect Biopharm LLC

NCT04040192 COMPLETED

A Study to Evaluate Long-Term Maintenance Treatment With Once Daily Crisaborole Ointment 2% in Pediatric and Adult Participants With Mild-to-Moderate Atopic Dermatitis

Pfizer n=620

NCT03661138 COMPLETED

A Study to Evaluate Safety of Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis

AbbVie n=272

NCT04250350 COMPLETED

Study to Assess the Safety and Efficacy of Lebrikizumab (LY3650150) in Adolescent Participants With Moderate-to-Severe Atopic Dermatitis

Eli Lilly and Company n=206

NCT05016284 WITHDRAWN

Comparison of JW-100 and EUCRISA for the Treatment of Atopic Dermatitis

Applied Biology, Inc.

NCT04146363 COMPLETED

Evaluation of the Efficacy and Safety of Lebrikizumab (LY3650150) in Moderate to Severe Atopic Dermatitis (ADvocate1)

Eli Lilly and Company n=424

NCT05219864 WITHDRAWN

Topical Ruxolitinib Evaluation in Chronic Hand Eczema Study 1

Incyte Corporation

NCT05233410 WITHDRAWN

Topical Ruxolitinib Evaluation in Chronic Hand Eczema Study 2

Incyte Corporation

NCT03559270 TERMINATED

A Study of Baricitinib (LY3009104) in Participants With Moderate to Severe Atopic Dermatitis

Eli Lilly and Company n=374

NCT03645057 COMPLETED

ASPIRE: PROs & Caregiver Burden in Children With Atopic Dermatitis

University of Rochester n=92

NCT03435081 COMPLETED

A Study of Baricitinib (LY3009104) in Adult Participants With Moderate to Severe Atopic Dermatitis

Eli Lilly and Company n=440

NCT03346434 COMPLETED

Safety, Pharmacokinetics and Efficacy of Dupilumab in Patients ≥6 Months to <6 Years With Moderate-to-Severe Atopic Dermatitis (Liberty AD PRESCHOOL)

Regeneron Pharmaceuticals n=202

NCT04345367 COMPLETED

Study of Abrocitinib Compared With Dupilumab in Adults With Moderate to Severe Atopic Dermatitis on Background Topical Therapy

Pfizer n=727

NCT04360187 COMPLETED

Crisaborole for Chinese and Japanese Subjects (≥2 Years of Age) With Mild to Moderate Atopic Dermatitis

Pfizer n=391

NCT04250337 COMPLETED

Safety and Efficacy of Lebrikizumab (LY3650150) in Combination With Topical Corticosteroid in Moderate-to-Severe Atopic Dermatitis.

Eli Lilly and Company n=228

NCT03796676 COMPLETED

JAK1 Inhibitor With Medicated Topical Therapy in Adolescents With Atopic Dermatitis

Pfizer n=287

NCT03107611 COMPLETED

Bioequivalence Study of Pimecrolimus Cream, 1% and Elidel® Cream, 1% in Mild to Moderate Atopic Dermatitis

Mylan Inc. n=654

NCT03961529 COMPLETED

Long-term Trial of OPA-15406 Ointment in Adult and Pediatric Patients With Atopic Dermatitis

Otsuka Pharmaceutical Co., Ltd. n=366

NCT03627767 COMPLETED

Study to Investigate Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years and Over With Moderate to Severe Atopic Dermatitis With the Option of Rescue Treatment in Flaring Subjects

Pfizer n=1,235

NCT04498403 TERMINATED

A Study of the Long-Term Safety of Crisaborole Ointment, 2% in Japanese Pediatric and Adult Participants With Mild to Moderate Atopic Dermatitis

Pfizer n=40

NCT03540160 TERMINATED

Study of the Long Term Safety of Serlopitant for the Treatment of Pruritus (Itch)

Vyne Therapeutics Inc. n=558

NCT04666675 WITHDRAWN

A Study of Oral Upadacitinib Tablets to Assess Change in Disease State in Participants Aged 12-75 Years With Moderate to Severe Atopic Dermatitis in Brazil

AbbVie

NCT01429701 COMPLETED

Effectiveness of Polymyxin B Sulphate + Prednisolone + Benzocaine + Clioquinol in Acute and Sub-acute Dermatitis Eczematous

EMS n=76

NCT03908970 COMPLETED

Comparison Trial of OPA-15406 Ointment in Adult Patients With Atopic DermatitisSyndrome

Otsuka Pharmaceutical Co., Ltd. n=364

NCT03911401 COMPLETED

Comparison Trial of OPA-15406 Ointment in Pediatric Patients With Atopic Dermatitis

Otsuka Pharmaceutical Co., Ltd. n=251

NCT03720470 COMPLETED

Study Evaluating Efficacy and Safety of PF-04965842 and Dupilumab in Adult Subjects With Moderate to Severe Atopic Dermatitis on Background Topical Therapy

Pfizer n=838

NCT03386032 COMPLETED

8-Week Atopic Dermatitis (AD) Treatment Study

Procter and Gamble n=65

NCT02755649 COMPLETED

A Study to Assess the Efficacy and Safety of Dupilumab in Participants With Severe Atopic Dermatitis (AD) That Are Not Controlled With Oral Cyclosporine A (CSA) or for Those Who Cannot Take Oral CSA Because it is Not Medically Advisable

Regeneron Pharmaceuticals n=325

NCT03334396 COMPLETED

A Study of Baricitinib (LY3009104) in Patients With Moderate to Severe Atopic Dermatitis

Eli Lilly and Company n=660

NCT03345914 COMPLETED

Study to Investigate the Efficacy and Safety of Dupilumab Administered With Topical Corticosteroids (TCS) in Participants ≥6 to <12 Years With Severe Atopic Dermatitis (AD)

Regeneron Pharmaceuticals n=367

NCT03733301 COMPLETED

A Study of Baricitinib (LY3009104) in Combination With Topical Corticosteroids in Adults With Moderate to Severe Atopic Dermatitis

Eli Lilly and Company n=329

NCT04468711 COMPLETED

Vitamin D in Egyptian Children With Atopic Dermatitis

National Hepatology & Tropical Medicine Research Institute n=92

NCT01257061 COMPLETED

Effectiveness of Clemastine Fumarate + Dexamethasone Compared to Dexchlorpheniramine Maleate in Eczema Treatment

EMS n=310

NCT02277769 COMPLETED

Study of Dupilumab (REGN668/SAR231893) Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis

Regeneron Pharmaceuticals n=708

NCT02791308 COMPLETED

Study of Equivalence of Generic Pimecrolimus Cream 1% and Elidel® 1% in Subjects With Mild to Moderate Atopic Dermatitis

Actavis Inc. n=587

NCT00817063 COMPLETED

Efficacy and Safety of a Retinoid in the Treatment of Severe Chronic Hand Eczema

Stiefel, a GSK Company n=599

NCT03575871 COMPLETED

Study Evaluating Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years And Older With Moderate to Severe Atopic Dermatitis

Pfizer n=391

NCT02395133 COMPLETED

A Study to Confirm the Efficacy and Safety of Different Dupilumab Dose Regimens in Adults With Atopic Dermatitis (AD)

Regeneron Pharmaceuticals n=422

NCT03334422 COMPLETED

Study of Baricitinib (LY3009104) in Patients With Moderate to Severe Atopic Dermatitis

Eli Lilly and Company n=615

NCT03349060 COMPLETED

Study to Evaluate Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years And Older With Moderate to Severe Atopic Dermatitis

Pfizer n=387

NCT03269773 COMPLETED

Safety and Efficacy of FURESTEM-AD Inj. in Patients With Moderate to Severe Chronic Atopic Dermatitis(AD)

Kang Stem Biotech Co., Ltd. n=197

NCT02896101 COMPLETED

Study of Generic Pimecrolimus Cream, 1% in the Treatment of Mild to Moderate Atopic Dermatitis

Glenmark Pharmaceuticals Ltd. India n=755

NCT02601703 COMPLETED

To Study Generic Tacrolimus Ointment, 0.1% in the Treatment of Moderate to Severe Atopic Dermatitis (Inflammation of Skin: Itchy, Red, Swollen, and Cracked Skin)

Glenmark Pharmaceuticals Ltd. India n=1,110

NCT03054428 COMPLETED

Efficacy and Safety of Dupilumab in Participants ≥12 to <18 Years of Age, With Moderate-to-severe Atopic Dermatitis

Regeneron Pharmaceuticals n=251

NCT02595073 COMPLETED

Clinical Study to Evaluate the Efficacy and Safety of Desoximetasone (DSXS) With Atopic Dermatitis

Sun Pharmaceutical Industries, Inc. n=124

NCT02965118 COMPLETED

CAPTAIN-AD: Clinical Study of AmorePacific's TRPV1 Antagonist in Atopic Dermatitis

Amorepacific Corporation n=240

NCT02835170 COMPLETED

Study of Autologous Total Immunoglobulin G Therapy for Atopic Dermatitis

Ajou University School of Medicine n=51

NCT01567995 COMPLETED

Randomised, Double-blind, Placebo-controlled Study of Topical Clobetasone Butyrate 0.05% Cream in Subjects With Eczema for Two Weeks to Evaluate the Efficacy and Safety

GlaxoSmithKline n=240

NCT02277743 COMPLETED

Study of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis

Regeneron Pharmaceuticals n=671

NCT02260986 COMPLETED

Study to Assess the Efficacy and Long-term Safety of Dupilumab (REGN668/SAR231893) in Adult Participants With Moderate-to-Severe Atopic Dermatitis

Regeneron Pharmaceuticals n=740

NCT03297502 COMPLETED

Safety and Bioequivalence of Pimecrolimus Cream 1% and Elidel R in Treatment of Mild to Moderate Atopic Dermatitis

Par Pharmaceutical, Inc. n=582

NCT01996748 COMPLETED

Clinical Study to Assess the Efficacy and Safety of DF277 Compared to Placebo in the Treatment of Otic Eczema

Salvat n=135

NCT02118766 COMPLETED

Safety and Efficacy of AN2728 Topical Ointment, 2% in Children, Adolescents, and Adults (Ages 2 Years and Older) With Atopic Dermatitis

Pfizer n=763

NCT02118792 COMPLETED

Safety and Efficacy of AN2728 Topical Ointment, 2% in Children, Adolescents, and Adults (Aged 2 Years and Older) With Atopic Dermatitis

Pfizer n=764

NCT02120833 COMPLETED

A Test to Determine the Usefulness and Safety of a Cream Used on Babies With Dry Itchy Skin

Johnson & Johnson Consumer and Personal Products Worldwide n=51

NCT02178215 COMPLETED

Effect of Holly Mangrove Shower Gel in Atopic Dermatitis Patients

Mahidol University n=30

NCT01230190 WITHDRAWN

Management of Eczema by Specific Probiotic Strains

Agentschap NL

NCT01638234 COMPLETED

Effectiveness of Melatonin for Sleep Disturbances in Children With Atopic Dermatitis

National Taiwan University Hospital n=48

NCT01772056 TERMINATED

Efficacy Study of Topical Twice Weekly Fluticasone Treatment to Reduce Relapse in Atopic Dermatitis in Children

Elena Rubio Gomis n=54

NCT01139450 COMPLETED

Study of 0417 Ointment in the Treatment of Atopic Dermatitis

Fougera Pharmaceuticals Inc. n=899

NCT01053247 COMPLETED

Study of 0416 Ointment in the Treatment of Atopic Dermatitis

Fougera Pharmaceuticals Inc. n=793

NCT02176551 WITHDRAWN

Study Comparing Product 0405 to a Vehicle Control in the Treatment of Mild to Moderate Atopic Dermatitis in Pediatric Subjects

Fougera Pharmaceuticals Inc.

NCT02176577 WITHDRAWN

Study to Determine the Pharmacokinetics of Product 0405

Fougera Pharmaceuticals Inc.

NCT02176538 WITHDRAWN

Study Comparing Product 0405 to a Vehicle Control in the Treatment of Mild to Moderate Atopic Dermatitis in Pediatric Subjects

Fougera Pharmaceuticals Inc.

NCT02116452 COMPLETED

Prebiotics in Prevention of Atopy

Federico II University n=380

NCT01779258 COMPLETED

Emollients in the Management of Atopic Dermatitis

Pierre Fabre Medicament n=347

NCT01244230 COMPLETED

Safety, Efficacy and Pharmacokinetic Study of Allegra in Pediatric Patients With Atopic Dermatitis (AD)

Sanofi n=100

NCT01467362 COMPLETED

Efficacy Emollient on Xerosis in Children With Atopic Dermatitis

Pierre Fabre Medicament n=251

NCT01500941 COMPLETED

Probiotics in Adults: do They Improve Atopic Dermatitis?

ASST Fatebenefratelli Sacco n=48

NCT01124318 COMPLETED

A Pilot Study of Lactofiltrum to Treat Atopic Dermatitis in Adults

Avva Rus, JSC n=90

NCT01137331 COMPLETED

K301 for the Treatment of Seborrhoeic Eczema (SE) of the Scalp

Moberg Pharma AB n=201

NCT07298395 RECRUITING

Study of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis

Enveda Therapeutics

NCT06863961 ACTIVE NOT RECRUITING

A Study to Assess the Efficacy and Safety of Afimkibart (RO7790121) in Participants With Moderate to Severe Atopic Dermatitis

Hoffmann-La Roche

NCT07223697 RECRUITING

A Long Term Extension Study to Evaluate the Safety and Efficacy of Afimkibart (RO7790121) in Participants With Atopic Dermatitis

Hoffmann-La Roche

NCT06395948 ACTIVE NOT RECRUITING

A Study Evaluating APG777 in Atopic Dermatitis

Apogee Therapeutics, Inc.

NCT07230860 RECRUITING

A Study of JNJ-95597528 in Participants With Moderate to Severe Atopic Dermatitis

Janssen Research & Development, LLC

NCT06136741 ACTIVE NOT RECRUITING

A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Adult Patients With Moderate-to-Severe Atopic Dermatitis

Nektar Therapeutics

NCT07277660 RECRUITING

A Dose-ranging Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Galvokimig in Adult Study Participants With Atopic Dermatitis

UCB Biopharma SRL

NCT06727552 ACTIVE NOT RECRUITING

A Study of Barzolvolimab in Patients With Atopic Dermatitis

Celldex Therapeutics

NCT01631617 RECRUITING

Effects of Treatments on Atopic Dermatitis

National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

NCT05995964 RECRUITING

A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic Dermatitis

Pfizer

NCT07003425 RECRUITING

A Long-term Safety and Efficacy Study Evaluating APG777 in Atopic Dermatitis

Apogee Therapeutics, Inc.

NCT07167758 ACTIVE NOT RECRUITING

A Study Evaluating TRIV-509 in Atopic Dermatitis

Triveni Bio

NCT07105488 RECRUITING

A Study Evaluating BFB759 in Moderate to Severe Atopic Dermatitis

Bluefin Biomedicine, Inc.

NCT07217015 RECRUITING

A Study of KT-621 Administered Orally to Participants With Moderate to Severe Atopic Dermatitis

Kymera Therapeutics, Inc.

NCT07321951 RECRUITING

A Study of SHR-1819 in Patients With Moderate-to-severe Atopic Dermatitis

Guangdong Hengrui Pharmaceutical Co., Ltd

NCT07211542 RECRUITING

A Study to Investigate the Efficacy and Safety of SHR-1905 in Patients With Moderate-to-severe Atopic Dermatitis

Guangdong Hengrui Pharmaceutical Co., Ltd

NCT07220577 ACTIVE NOT RECRUITING

Phase 2a Study to Assess the Efficacy,Safety and Tolerability of GIA632 in Adult Participants With Moderate to Severe Atopic Dermatitis

Novartis Pharmaceuticals

NCT07445919 RECRUITING

A Clinical Study to Evaluate SM17 for Atopic Dermatitis

SinoMab BioScience Ltd

NCT07502222 NOT YET RECRUITING

A Study to Evaluate the Efficacy and Safety of AK139 in Patients With Moderate-to-severe Atopic Dermatitis

Akeso

NCT07011706 ACTIVE NOT RECRUITING

ATI-045 Versus Placebo in Patients With Moderate-to-Severe Atopic Dermatitis

Aclaris Therapeutics, Inc.

NCT06881251 ACTIVE NOT RECRUITING

A Study of JNJ-95475939 in the Treatment of Participants With Moderate to Severe Atopic Dermatitis (AD)

Janssen Research & Development, LLC

NCT07330934 RECRUITING

A Study to Evaluate Efficacy and Safety of IBI356 in Participants With Moderate to Severe Atopic Dermatitis

Innovent Biologics (Suzhou) Co. Ltd.

NCT07465120 NOT YET RECRUITING

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase Ⅱ Clinical Study to Evaluate the Efficacy and Safety of CMS-D001 in Adult Patients With Moderate to Severe Atopic Dermatitis

Dermavon Holdings Limited

NCT07441395 RECRUITING

Study to Evaluate Soquelitinib in Participants With Moderate to Severe AD

Corvus Pharmaceuticals, Inc.

NCT03742414 ACTIVE NOT RECRUITING

Seal, Stopping Eczema and Allergy Study

Kari Nadeau, MD, PhD

NCT07216027 ACTIVE NOT RECRUITING

A Study to Learn About Study Medicine Called PF-08049820 in People With Eczema

Pfizer

NCT06024499 ACTIVE NOT RECRUITING

Phase 2 Trial of HY209gel in Atopic Dermatitis Patients

Shaperon

NCT06718101 ACTIVE NOT RECRUITING

A Study to Evaluate the Effectiveness and Safety of Treatments, Either Alone or in Combination, for the Treatment of Moderate to Severe Atopic Dermatitis

AbbVie

NCT07037901 RECRUITING

A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis

Inmagene LLC

NCT07399067 RECRUITING

A Proof-of-Concept Study of IBI3002 in Patients With Moderate to Severe Atopic Dermatitis

Innovent Biologics (Suzhou) Co. Ltd.

NCT06094179 ACTIVE NOT RECRUITING

Evaluate the Safety, Tolerability of BAT6026

Bio-Thera Solutions

NCT07193589 RECRUITING

A Phase II Clinical Study Evaluating of ZL-82 Tablets in Atopic Dermatitis

Chengdu Zenitar Biomedical Technology Co., Ltd

NCT07242638 RECRUITING

Treatment of Atopic Dermatitis and Alopecia Areata With Abrocitinib in Individuals With Down Syndrome

Icahn School of Medicine at Mount Sinai

NCT06096857 RECRUITING

Cardamom and Topical Roseomonas in Atopic Dermatitis

National Institute of Allergy and Infectious Diseases (NIAID)

NCT07355075 RECRUITING

A Double-Blind, Randomized, Vehicle-Controlled Phase 2 Study to Assess the Efficacy and Safety of GX-03 in Adult Subjects With Moderate to Severe Atopic Dermatitis (Eczema)

Turn Therapeutics

NCT07344051 NOT YET RECRUITING

A Phase II Study of QLS12010 Capsules in Adults With Moderate to Severe Atopic Dermatitis

Qilu Pharmaceutical Co., Ltd.

NCT06996912 ACTIVE NOT RECRUITING

A Study for HSK44459 in Participants With Atopic Dermatitis

Xizang Haisco Pharmaceutical Co., Ltd

NCT07297602 RECRUITING

Evaluation of Efficacy and Safety of Oral Roflumilast for Treatment of Moderate to Severe Atopic Dermatitis in Patients Aged 12 Years and Older: A Pilot Study

Nora Mohamed Abdelrazik

NCT06947993 RECRUITING

Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis

Novartis Pharmaceuticals

NCT06324812 ACTIVE NOT RECRUITING

Evaluation of 611 in Chinese Children and Adolescents With Moderate to Severe Atopic Dermatitis

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

NCT07230483 RECRUITING

A Long-term Safety and Efficacy Study Evaluating CM512 in Atopic Dermatitis.

Keymed Biosciences Co.Ltd

NCT07175233 NOT YET RECRUITING

A Phase 2 Study to Evaluate the Efficacy, Safety of SIM0278 in Subjects With Moderate to Severe Atopic Dermatitis

Jiangsu Simcere Pharmaceutical Co., Ltd.

NCT04600362 ACTIVE NOT RECRUITING

Study of Dupilumab to Demonstrate Efficacy in Subjects With Nummular Eczema

Technical University of Munich

NCT06397911 RECRUITING

Evaluate Efficacy and Safety of Repeat Subcutaneous Doses of FB825 in Adults With Moderate-to-Severe Atopic Dermatitis

Oneness Biotech Co., Ltd.

NCT06947980 RECRUITING

Study of CM512 in Patients With Moderate-to-Severe Atopic Dermatitis

Keymed Biosciences Co.Ltd

NCT07103174 NOT YET RECRUITING

A Study of MG-K10 Humanized Monoclonal Antibody Injection in Subjects With Atopic Dermatitis

Shanghai Mabgeek Biotech.Co.Ltd

NCT06855745 RECRUITING

Phase 2 Randomized Double-blind Study to Assess Topical Zabalafin Hydrogel Vs Vehicle in Mild to Moderate AD.

Alphyn Biologics

NCT07073677 NOT YET RECRUITING

A Study to Evaluate the Efficacy and Safety of IN-115314 Ointment in Mild to Moderate Atopic Dermatitis Adult Patients

HK inno.N Corporation

NCT06713499 RECRUITING

A Phase Ib/II Study to Investigate the Safety of SHR-1819 in Children and Adolescents With Moderate-to-severe Atopic Dermatitis

Guangdong Hengrui Pharmaceutical Co., Ltd

NCT07054736 NOT YET RECRUITING

Evaluate the Efficacy and Safety of XKH001 Injection in Patients With Moderate-to-Severe Atopic Dermatitis

Zhejiang Kanova Biopharmaceutical Co., LTD

NCT06584552 RECRUITING

LaCE (Lactobacillus Paracasei LPB27 On Early Childhood Eczema)

The University of New South Wales

NCT06994520 ACTIVE NOT RECRUITING

Efficacy of Topical Cannabidiol for Eczema

Khon Kaen University

NCT06931990 NOT YET RECRUITING

A Study to Explore the Safety, Tolerability, Efficacy, and Pharmacokinetics of LT-002-158 Tablets in Chinese Adult Subjects With Atopic Dermatitis

Leadingtac Pharmaceutical (Shaoxing) Co., Ltd.

NCT06158490 ENROLLING BY INVITATION

A Study to Evaluate JYP0061 Tablets in Patients With Moderate-to-severe Atopic Dermatitis

Guangzhou JOYO Pharma Co., Ltd

NCT06524635 RECRUITING

A Study to Assess Molecular Changes in Adult Participants With Moderate to Severe Hidradenitis Suppurativa or With Moderate to Severe Atopic Dermatitis Receiving Subcutaneous Injections of Lutikizumab

AbbVie

NCT06765005 RECRUITING

IB/IIa Study of MG-K10 in Adolescent Moderately Severe Patients

Shanghai Mabgeek Biotech.Co.Ltd

NCT06758752 ACTIVE NOT RECRUITING

A Herbal Compound for Eczema

Fasa University of Medical Sciences

NCT06756126 NOT YET RECRUITING

A Clinical Study of AK120 in Adolescents With Moderate-to-severe Atopic Dermatitis (AD)

Akeso

NCT06176040 ACTIVE NOT RECRUITING

A Study of TAVO101 in Atopic Dermatitis Patients

Tavotek Biotherapeutics

NCT06487000 NOT YET RECRUITING

Determine the Dose-dependent Efficacy and Safety of EC-18 in Patients With Moderate to Severe Atopic Dermatitis

Enzychem Lifesciences Corporation

NCT05509023 ACTIVE NOT RECRUITING

Evaluating Safety and Efficacy of ADX-914 in Patients With Moderate to Severe Atopic Dermatitis (SIGNAL-AD)

Q32 Bio Inc.

NCT02365246 RECRUITING

Treatment of AD With IgE Specific Immunoadsorption (IGEIAAD)

Universitaire Ziekenhuizen KU Leuven

NCT04137562 ACTIVE NOT RECRUITING

Safety and Efficacy in Patients With Moderate to Severe Subacute and Chronic Atopic Dermatitis

EHL Bio Co., Ltd.

NCT07598383 NOT YET RECRUITING

A Multicenter, Randomized, Double-blind, Vehicle Controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of VC005 Gel in Adult Subjects With Mild to Moderate Atopic Dermatitis

Jiangsu vcare pharmaceutical technology co., LTD

NCT07599813 RECRUITING

A Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis

Apollo Therapeutics Ltd

NCT05549947 COMPLETED

Efficacy and Safety Study of SHR-1819 Injection in Adult Patients With Severe Atopic Dermatitis

Shanghai Hengrui Pharmaceutical Co., Ltd.

NCT07158151 COMPLETED

A Phase II Trial of the Safety and Efficacy of RSS0309 Ointment in Adults With Atopic Dermatitis

Reistone Biopharma Company Limited

NCT02664805 COMPLETED

Proof of Concept, Twice Daily Applications of LEO 124249 Ointment in the Treatment of Chronic Hand Eczema

LEO Pharma

NCT06891040 COMPLETED

Phase II Clinical Study to Evaluate the Efficacy and Safety of VC005 in Adult Subjects With Mild to Moderate Atopic Dermatitis

Jiangsu vcare pharmaceutical technology co., LTD

NCT04643457 COMPLETED

A Study to Test the Safety, Pharmacokinetics, and Efficacy of UCB9741 in Healthy Study Participants and in Study Participants With Atopic Dermatitis

UCB Biopharma SRL

NCT06810050 COMPLETED

Phase 2b Safety and Efficacy Study of CGB-500 Topical Ointment With 0.5% and 1% Tofacitnib for Treatment of Atopic Dermatitis

CAGE Bio Inc.

NCT06923228 COMPLETED

A Study to Assess Efficacy and Safety of CGB-500, 1% Tofacitinib Versus an Active Comparator for Atopic Dermatitis

CAGE Bio Inc.

NCT05399368 TERMINATED

An Efficacy and Safety Study of RPT193 in Adults With Atopic Dermatitis

RAPT Therapeutics, Inc.

NCT06700499 COMPLETED

A Study to Evaluate the Efficacy and Safety of AK120 in Subjects With Moderate to Severe Atopic Dermatitis

Akeso

NCT06585202 COMPLETED

Study of ATI-2138 in Adult Participants With Moderate to Severe Atopic Dermatitis

Aclaris Therapeutics, Inc.

NCT06012812 COMPLETED

A Study to Extend Efficacy and Safety of SHR-1819 Injection in Adult Patients With Moderate to Severe Atopic Dermatitis

Shanghai Hengrui Pharmaceutical Co., Ltd.

NCT05923099 COMPLETED

A Trial to Evaluate the Efficacy and Safety of Different Doses of LEO 138559 in Adults With Moderate-to-severe Atopic Dermatitis

LEO Pharma

NCT06283550 COMPLETED

Efficacy, Safety, and Tolerability of Abrocitinib in Subjects With Moderate to Severe Chronic Hand Eczema Refractory to Corticosteroid Therapy

Innovaderm Research Inc.

NCT05388760 COMPLETED

Tralokinumab Monotherapy for Children With Moderate-to-severe Atopic Dermatitis - TRAPEDS 1 (TRAlokinumab PEDiatric Trial no. 1)

LEO Pharma

NCT07071610 COMPLETED

A Study to Evaluate the Efficacy and Safety of LNK01004 Ointment in Adults With Atopic Dermatitis

Lynk Pharmaceuticals Co., Ltd

NCT04684485 COMPLETED

To Assess the Efficacy and Safety of SCD-044 in the Treatment of Moderate to Severe Atopic Dermatitis

Sun Pharmaceutical Industries Limited

NCT06309355 COMPLETED

Topical YR001 Ointment in Adult With Mild to Moderate Atopic Dermatitis

Hangzhou Yirui Pharmaceutical Technology Co., Ltd

NCT04246372 COMPLETED

Tofacitinib for Immune Skin Conditions in Down Syndrome

University of Colorado, Denver

NCT06058156 TERMINATED

Phase 2 Study of SAR444656 in Adult Participants With Moderate to Severe Atopic Dermatitis

Sanofi

NCT06998056 COMPLETED

Safety Study of Roflumilast Cream 0.05% in Infants Aged 3 Months to Less Than 2 Years With Atopic Dermatitis

Arcutis Biotherapeutics, Inc.

NCT06723405 COMPLETED

Efficacy Study of EVO301 in Moderate to Severe Atopic Dermatitis

Evommune, Inc.

NCT05911841 TERMINATED

A Study of LY3454738 in the Treatment of Adult Participants With Moderate-to-Severe Atopic Dermatitis

Eli Lilly and Company

NCT05003804 COMPLETED

Allergic Disease Onset Prevention Study

Siolta Therapeutics, Inc.

NCT06447506 TERMINATED

Long-Term Study (AtDvance) to Evaluate GSK1070806 in Atopic Dermatitis.

GlaxoSmithKline

NCT05999799 TERMINATED

A Dose Finding Study to Investigate the Safety and Effectiveness of GSK1070806 in Adult Participants With Moderate to Severe Atopic Dermatitis

GlaxoSmithKline

NCT05984784 TERMINATED

A Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of IMG-007 in Adults With Atopic Dermatitis (AD)

Inmagene LLC

NCT05277571 COMPLETED

A Single-ascending Dose (Part A) and Repeat-dose (Part B) Study to Investigate the Safety, Pharmacokinetics and Efficacy (Part B Only) of UCB1381 in Healthy Study Participants (Part A) and in Study Participants With Moderate to Severe Atopic Dermatitis (Part B)

UCB Biopharma SRL

NCT03822832 COMPLETED

A Study in Patients With Atopic Eczema to Test How Effective BI 655130 is and How Well it is Tolerated

Boehringer Ingelheim

NCT05932654 COMPLETED

POC Study to Evaluate BSI-045B in Moderate-to-severe Atopic Dermatitis

Biosion, Inc.

NCT07186387 COMPLETED

Study of LW402 in Moderate-to-Severe Atopic Dermatitis

Shanghai Longwood Biopharmaceuticals Co., Ltd.

NCT07182864 COMPLETED

MH004 Ointment in Healthy Adult Volunteers and Participants With Mild to Moderate Atopic Dermatitis

Minghui Pharmaceutical (Hangzhou) Ltd

NCT06436183 COMPLETED

A Study of the Effects of Camoteskimab in Adults With Moderate to Severe Atopic Dermatitis

Apollo Therapeutics Ltd

NCT04992546 COMPLETED

Phase 2a Study of the Safety, Tolerability, and Pharmacokinetics of Topically Administered PRN473 (SAR444727) in Patients With Mild to Moderate Atopic Dermatitis

Principia Biopharma, a Sanofi Company

NCT05186805 COMPLETED

Maximal Use Study of Tapinarof Cream, 1% in Pediatric Subjects With Extensive Atopic Dermatitis

Organon and Co

NCT06144424 COMPLETED

Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of EP262 in Subjects With Atopic Dermatitis

Escient Pharmaceuticals, Inc

NCT03563066 COMPLETED

Effect of Benralizumab in Atopic Dermatitis

McMaster University

NCT05240300 WITHDRAWN

A Study of Topical BX005-A in Subjects With Moderate to Severe Atopic Dermatitis

BiomX, Inc.

NCT05906628 COMPLETED

Topical Ruxolitinib Evaluation in Chronic Hand Eczema

Incyte Corporation

NCT04194814 COMPLETED

Skin bioMARkers for Atopic Eczema Therapy Evaluation

Sheffield Teaching Hospitals NHS Foundation Trust

NCT04921345 COMPLETED

Pharmacokinetics, Safety and Efficacy of Nemolizumab in Participants With Moderate-to-Severe Atopic Dermatitis

Galderma R&D

NCT05131477 COMPLETED

Study Testing Response Effect of KY1005 Against Moderate-to-Severe Atopic Dermatitis, The STREAM-AD Study

Kymab Limited

NCT04365387 COMPLETED

A Study to Assess Immunization Responses in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis Treated With Nemolizumab

Galderma R&D

NCT01179880 COMPLETED

A Study of E6005 in Japanese Patients With Atopic Dermatitis

Organon and Co

NCT02094235 COMPLETED

A Phase 1/2 Study of E6005 in Pediatric Subjects With Atopic Dermatitis

Organon and Co

NCT01461941 COMPLETED

A Phase 2 Study of E6005 in Patients With Atopic Dermatitis

Organon and Co

NCT05870865 COMPLETED

A Study to Evaluate the Anti-pruritic Effectiveness of ASN008 in Adults With Mild to Moderate Atopic Dermatitis

Formation Bio, Inc.

NCT04313400 COMPLETED

Topically Applied AMTX-100 CF for Adult Patients With Mild to Moderate Atopic Dermatitis

Amytrx Therapeutics, Inc.

NCT06363461 COMPLETED

Study of TDM-180935 in Atopic Dermatitis Patients

Technoderma Medicines Inc.

NCT01568489 COMPLETED

Phase 2 Study of HL-009 Liposomal Gel to Treat Mild to Moderate Atopic Dermatitis

HanAll BioPharma Co., Ltd.

NCT04369846 COMPLETED

A Phase I/IIa Study to Investigate the GM-XANTHO in Healthy Volunteers and Atopic Dermatitis Patients

Xantho Biotechnology Co., LTD

NCT04922021 COMPLETED

An Evaluation of LEO 138559 in Adults With Moderate to Severe Atopic Dermatitis.

LEO Pharma

NCT03725722 COMPLETED

Dose-ranging Trial to Evaluate Delgocitinib Cream 1, 3, 8, and 20 mg/g Compared to Delgocitinib Cream Vehicle Over an 8-week Treatment Period in Adult Subjects With Atopic Dermatitis.

LEO Pharma

NCT03683719 COMPLETED

Phase 2b Dose-ranging Trial to Evaluate Delgocitinib Cream 1, 3, 8, and 20 mg/g Compared to Delgocitinib Cream Vehicle Over a 16-week Treatment Period in Adult Subjects With Chronic Hand Eczema

LEO Pharma

NCT06058000 COMPLETED

A Phase 2 Study of QLM3003 Ointment in Participants With Mild or Moderate Atopic Dermatitis

Qilu Pharmaceutical Co., Ltd.

NCT03562377 COMPLETED

Vaccine Responses in Tralokinumab-Treated Atopic Dermatitis - ECZTRA 5 (ECZema TRAlokinumab Trial No. 5)

LEO Pharma

NCT05470114 COMPLETED

A Multi-omics Disease Signature Trial in Adult Patients With Moderate to Severe AD

LEO Pharma

NCT01037881 COMPLETED

LEO 29102 Cream in the Treatment of Atopic Dermatitis

LEO Pharma

NCT05469464 COMPLETED

Study to Assess the Efficacy and Safety of Orismilast in Atopic Dermatitis (ADESOS)

UNION therapeutics

NCT06035354 COMPLETED

A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of AK120 in Subjects With Atopic Dermatitis

Akeso

NCT05579899 COMPLETED

Safety and Efficacy Study of EVO101 Topical Cream in Atopic Dermatitis

Evommune, Inc.

NCT05048056 TERMINATED

Phase 2 Study of Efficacy and Safety of AK120, in Subjects With Moderate-to-Severe Atopic Dermatitis

Akesobio Australia Pty Ltd

NCT03830177 COMPLETED

Safety and Efficacy of a Topical Scalp Treatment for Dry Scalp Conditions in Children and Adult

Ann & Robert H Lurie Children's Hospital of Chicago

NCT04086121 TERMINATED

A Study to Test the Long-term Safety of BI 655130 in Patients With Atopic Eczema Who Took Part in Study 1368-0032

Boehringer Ingelheim

NCT05656911 COMPLETED

A Study to Learn How Well the Study Treatment Zabedosertib (BAY1834845) Works and How Safe it is Compared to Placebo in Adult Participants With Moderate-to-severe Atopic Dermatitis

Bayer

NCT05935085 TERMINATED

This Study Will Evaluate the Safety, Tolerability, and Efficacy of ANB032 in Subjects with Moderate to Severe Atopic Dermatitis (AD).

AnaptysBio, Inc.

NCT05487963 COMPLETED

Tolerability and Effectiveness of CGB-500 Topical Ointment, 1% Tofacitinib, for the Treatment of Atopic Dermatitis

CAGE Bio Inc.

NCT04021862 COMPLETED

A Study to Evaluate the Safety and Efficacy of Bermekimab in Patients With Moderate to Severe Atopic Dermatitis

Janssen Research & Development, LLC

NCT04490109 COMPLETED

B244 Topical Spray for the Treatment of Pruritus in Adults With a History of Atopic Dermatitis

AOBiome LLC

NCT04562116 COMPLETED

A Study to Assess the Effects of Nemolizumab on Cytochrome P450 Substrates in Participants With Moderate-to-Severe Atopic Dermatitis

Galderma R&D

NCT03861455 COMPLETED

Efficacy and Safety of Dupilumab Chronic Hands Eczema Refractory to Highly Potent Topical Corticosteroids

University Hospital, Toulouse

NCT03553615 WITHDRAWN

Open-label Pilot Clinical Trial of Oral Ivermectin to Treat Atopic Dermatitis

Stanford University

NCT06092762 COMPLETED

A Study to Evaluate the Safety and Efficacy of AK120 in Subjects With Moderate to Severe Atopic Dermatitis

Akeso

NCT05579925 COMPLETED

A Study of CM310 in Children Patients With Moderate-to-severe Atopic Dermatis

Keymed Biosciences Co.Ltd

NCT04893707 COMPLETED

The Study of CM310 in Patients With Atopic Dermatitis

Keymed Biosciences Co.Ltd

NCT05717920 COMPLETED

A Clinical Trial in Subjects With Atopic Dermatitis (Part 1)

Aldeyra Therapeutics, Inc.

NCT05432596 COMPLETED

Study of ATI-1777 in Patients 12 to 65 Years Old With Mild to Severe Atopic Dermatitis

Aclaris Therapeutics, Inc.

NCT05715320 COMPLETED

Study of CM310 Injection in Subjects With Moderate-to-Severe Atopic Dermatitis

Keymed Biosciences Co.Ltd

NCT06162507 COMPLETED

Study of CM310 in Children Subjects With Moderate-to-severe Atopic Dermatis

Keymed Biosciences Co.Ltd

NCT05155085 TERMINATED

A Study to Assess Subcutaneous Lirentelimab (AK002) in Atopic Dermatitis

Allakos Inc.

NCT05375955 COMPLETED

A Study to Learn About The Study Medicine (PF-07038124) In Patients With Mild To Moderate Atopic Dermatitis Or Mild To Severe Plaque Psoriasis.

Pfizer

NCT05127421 COMPLETED

Ruxolitinib Cream in Participants With Facial and/or Neck Atopic Dermatitis Involvement

Incyte Corporation

NCT05997927 COMPLETED

Efficacy and Safety Clinical Study of VC005 Tablets in Adult Patients With Moderate to Severe Atopic Dermatitis

Jiangsu vcare pharmaceutical technology co., LTD

NCT05018806 COMPLETED

Proof of Concept Study of Rilzabrutinib in Adult Patients With Moderate-to-severe Atopic Dermatitis

Sanofi

NCT04836858 COMPLETED

A Study to Assess the Efficacy and Safety of CMK389 in Patients With Moderate to Severe Atopic Dermatitis.

Novartis Pharmaceuticals

NCT02651714 COMPLETED

Tradipitant in Treatment-resistant Pruritus Associated With Atopic Dermatitis

Vanda Pharmaceuticals

NCT02004041 COMPLETED

Proof of Concept of VLY-686 in Subjects With Treatment-Resistant Pruritus Associated With Atopic Dermatitis

Vanda Pharmaceuticals

NCT05117060 COMPLETED

Efficacy and Safety of LEO 152020 Tablets for the Treatment of Adults With Moderate to Severe Atopic Dermatitis

JW Pharmaceutical

NCT05017480 COMPLETED

A Study to Evaluate the Efficacy and Safety of CBP-201 in Moderate to Severe Atopic Dermatitis in China

Connect Biopharm LLC

NCT05158023 COMPLETED

Phase 2b Study of ASLAN004 in Adults With Moderate-to-Severe Atopic Dermatitis

ASLAN Pharmaceuticals

NCT03703102 COMPLETED

Study of an Anti-OX40 Monoclonal Antibody (KHK4083) in Subjects With Moderate to Severe Atopic Dermatitis

Kyowa Kirin, Inc.

NCT04306965 COMPLETED

Apremilast 30 mg Twice Daily (BID) Combined With Dupilumab

Tufts Medical Center

NCT05491447 TERMINATED

A Clinical Trial of BMX-010 in Adult Subjects With Atopic Dermatitis

BioMimetix JV, LLC

NCT04378569 COMPLETED

Safety and Efficacy of ARQ-252 Cream in Subjects With Chronic Hand Eczema

Arcutis Biotherapeutics, Inc.

NCT04435392 COMPLETED

Jaktinib Hydrochloride Cream For Atopic Dermatitis

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

NCT05769946 COMPLETED

A Study of Hemay005 in Adult With Atopic Dermatitis

Ganzhou Hemay Pharmaceutical Co., Ltd

NCT04352595 COMPLETED

A Phase Ⅱ Study of Hemay808 for Atopic Dermatitis Patients

Tianjin Hemay Pharmaceutical Co., Ltd

NCT05544591 COMPLETED

Evaluation of 611 in Chinese Adults With Moderate to Severe Atopic Dermatitis

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

NCT04800315 COMPLETED

A Study to Evaluate Safety and Effectiveness of Cendakimab (CC-93538) in Participants With Moderate to Severe Atopic Dermatitis

Celgene

NCT04220411 TERMINATED

A Study for AR100DP1 in Mild to Moderate Atopic Dermatitis (AD)

Arjil Pharmaceuticals LLC

NCT04149522 TERMINATED

Evaluation of Mepitel Film® in Preventing Epidermitis in Patients Receiving Radiation Therapy for Breast Cancer

Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)

NCT05253755 TERMINATED

Study the Safety and Efficacy of DBI-001 Gel Versus Aqueous Gel

DermBiont, Inc.

NCT04839380 COMPLETED

The Purpose of the Study is to Evaluate the Effect of Ruxolitinib Cream on Itch in Participants With Atopic Dermatitis

Incyte Corporation

NCT01408511 COMPLETED

HPA Axis Study in Adults

Bayer

NCT06085521 COMPLETED

A Study of LNK01001 Capsule in Patients With Moderate to Severe Atopic Dermatitis

Lynk Pharmaceuticals Co., Ltd

NCT05014438 COMPLETED

A Study of BMS-986166 or Branebrutinib for the Treatment of Participants With Atopic Dermatitis

Bristol-Myers Squibb

NCT04598269 COMPLETED

Study of ATI-1777 in Adult Patients With Moderate or Severe Atopic Dermatitis

Aclaris Therapeutics, Inc.

NCT04212169 COMPLETED

Efficacy and Safety of MEDI3506 in Adult Subjects With Atopic Dermatitis

AstraZeneca

NCT01407510 COMPLETED

HPA Axis Study in Japanese Adults

Bayer

NCT03654755 TERMINATED

Study to Evaluate Long-Term Safety of ASN002 in Subjects With Moderate to Severe Atopic Dermatitis

Asana BioSciences

NCT05439941 TERMINATED

A Long-Term Extension Trial in Participants With Atopic Dermatitis Who Participated in Previous EDP1815 Trials

Evelo Biosciences, Inc.

NCT04605094 TERMINATED

Efficacy and Safety Study of the Use of Benralizumab for Patients With Moderate to Severe Atopic Dermatitis

AstraZeneca

NCT05121480 COMPLETED

A Study Investigating the Effect of EDP1815 in the Treatment of Mild, Moderate and Severe Atopic Dermatitis

Evelo Biosciences, Inc.

NCT05222516 TERMINATED

Immunomodulation by OM-85 (Broncho-Vaxom) in Early AD

OM Pharma SA

NCT04444752 COMPLETED

A Study to Assess the Efficacy and Safety of CBP-201 in Adult Subjects With Moderate to Severe Atopic Dermatitis

Connect Biopharm LLC

NCT03531957 COMPLETED

Phase 2B Study to Evaluate ASN002 in Subjects With Moderate to Severe Atopic Dermatitis (RADIANT)

Asana BioSciences

NCT04737304 COMPLETED

A First-in-Human PoC Study With BEN2293 in Patients With Mild to Moderate Atopic Dermatitis

BenevolentAI Bio

NCT04179760 COMPLETED

Safety and Efficacy of SCM-AGH in Subjects With Moderate to Severe Atopic Dermatitis

SCM Lifescience Co., LTD.

NCT00944632 COMPLETED

Dose Escalation of Different Concentrations of ZK 245186 in Atopic Dermatitis

Bayer

NCT04990440 TERMINATED

A Study of Bermekimab for the Treatment of Adult Participants With Moderate-to-Severe Atopic Dermatitis

Janssen Research & Development, LLC

NCT03533751 COMPLETED

Efficacy, Safety, and Pharmacokinetic Profile of Etokimab (ANB020) in Adult Participants With Moderate-to-Severe Atopic Dermatitis

AnaptysBio, Inc.

NCT04162899 COMPLETED

A Phase II Study in Adult Patients With Moderate to Severe Atopic Dermatitis

Reistone Biopharma Company Limited

NCT03747575 COMPLETED

A Study to Assess the Efficacy and Safety of MSTT1041A in Participants With Moderate to Severe Atopic Dermatitis

Genentech, Inc.

NCT03250624 COMPLETED

Safety and Efficacy of CD5024 0.3% Cream in Subjects With Atopic Dermatitis

Galderma R&D

NCT03921411 COMPLETED

A Pharmacokinetics and Safety Study of Nemolizumab in Adolescent Participants With Atopic Dermatitis (AD)

Galderma R&D

NCT04556461 COMPLETED

Effects of Tralokinumab Treatment of Atopic Dermatitis on Skin Barrier Function

Prof. Dr. Stephan Weidinger

NCT04325802 WITHDRAWN

Treatment of Chronic Itch in Atopic Dermatitis With Opioid Antagonist Naltrexone

University of Minnesota

NCT04539639 COMPLETED

Clinical Study of Jaktinib in the Treatment of Patients With Moderate and Severe Atopic Dermatitis

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

NCT02537509 COMPLETED

PRAgmatic Trial in Atopic Dermatitis Testing Long-term Control Effectiveness of New Phototherapy Regimen During Winter Coupled With Oral Vitamin D Supplementation vs. Placebo

Rennes University Hospital

NCT04791319 TERMINATED

A Study of Bermekimab (JNJ-77474462) in the Treatment of Participants With Moderate to Severe Atopic Dermatitis

Janssen Research & Development, LLC

NCT03916081 COMPLETED

Safety and Efficacy of ARQ-151 Cream in Adolescents and Adults With Atopic Dermatitis

Arcutis Biotherapeutics, Inc.

NCT03614221 COMPLETED

Comparison of Lindioil (Indigo Naturalis Oil Extract) Ointment to Protopic® Ointment 0.1% in Treating Atopic Dermatitis

Chang Gung Memorial Hospital

NCT03915496 COMPLETED

Study Evaluating the Mechanism of Action of PF-04965842 Monotherapy for Moderate-to-severe Atopic Dermatitis

Pfizer

NCT03754309 COMPLETED

A Study of KY1005 in Patients With Moderate to Severe Atopic Dermatitis

Kymab Limited

NCT05641558 COMPLETED

Evaluation of 611 in Chinese Adult Patients With Moderate-to-Severe Atopic Dermatitis

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

NCT03817190 TERMINATED

Efficacy and Safety of Orally Administered DS107 in Adult Patients With Moderate to Severe Atopic Dermatitis

DS Biopharma

NCT02925793 COMPLETED

Safety and Efficacy Study of Topically Applied DS107 Cream in Mild to Moderate Atopic Dermatitis Patients (AD)

DS Biopharma

NCT04162769 COMPLETED

A Study to Assess the Safety and Efficacy of Etrasimod in Subjects With Moderate-to-Severe Atopic Dermatitis

Arena Pharmaceuticals

NCT03824405 COMPLETED

Study of the Safety, Tolerability and Efficacy of BTX 1204 in Patients With Moderate Atopic Dermatitis

Botanix Pharmaceuticals

NCT01905631 COMPLETED

Blinded, Randomized Study Evaluating Aurstat Versus Control in the Treatment of Atopic Dermatitis Associated Pruritus

The Center for Clinical and Cosmetic Research

NCT04693195 COMPLETED

A Multiple-Dose Study of BLU-5937 in Chronic Pruritus Associated With Atopic Dermatitis

Bellus Health Inc. - a GSK company

NCT02864498 COMPLETED

Efficacy and Safety Study of Orally Administered DS107 in Moderate to Severe Atopic Dermatitis Patients

DS Biopharma

NCT03235024 COMPLETED

Study to Determine Safety and Efficacy of B244 in Subjects With Mild to Moderate Atopic Dermatitis

AOBiome LLC

NCT02211417 COMPLETED

Oral DS107 in Moderate to Severe Atopic Dermatitis

Dignity Sciences Ltd.

NCT04927572 COMPLETED

Safety, Pharmacokinetics and Efficacy of FMX114 Versus Vehicle in Adults With Atopic Dermatitis

Vyne Therapeutics Inc.

NCT04664153 COMPLETED

Study To Assess Efficacy, Safety, Tolerability And Pharmacokinetics Of PF-07038124 Ointment In Participants With Atopic Dermatitis Or Plaque Psoriasis

Pfizer

NCT03568162 COMPLETED

Phase 2b Study to Evaluate the Efficacy and Safety of ISB 830 in Adults With Moderate to Severe Atopic Dermatitis

Ichnos Sciences SA

NCT04753034 COMPLETED

Study of TER-101 Topical Ointment in Subjects With Atopic Dermatitis

Teres Bio, Inc.

NCT00919763 COMPLETED

Efficacy and Safety Study of CD2027 Ointment 3 Microgram Per Gram (mcg/g) Twice Daily Treatment for Adults With at Least Moderate Atopic Dermatitis

Galderma R&D

NCT03738423 TERMINATED

Efficacy, Safety, and Pharmacokinetic Profiles of REGN3500 Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis

Regeneron Pharmaceuticals

NCT04805411 COMPLETED

Subcutaneously CM310/Placebo in Patients With Moderate-to-Severe Atopic Dermatitis (AD)

Keymed Biosciences Co.Ltd

NCT05059509 COMPLETED

Evaluate Efficacy of FB825 in Adults With Atopic Dermatitis

Oneness Biotech Co., Ltd.

NCT04018027 COMPLETED

Study to Evaluate the Efficacy and Safety of Oral Difelikefalin (CR845) for Moderate to Severe Pruritus in Subjects With Atopic Dermatitis

Cara Therapeutics, Inc.

NCT05276323 COMPLETED

Medihoney® Derma Cream Treatment for Mild to Moderate Atopic Dermatitis in Children Study

Soroka University Medical Center

NCT03809663 TERMINATED

A Dose Ranging Placebo-Controlled Double-Blind Study to Evaluate the Safety and Efficacy of Tezepelumab in Atopic Dermatitis

Amgen

NCT04530643 COMPLETED

A Phase II Study of HY209 Gel for Atopic Dermatitis Patients (Shaperon)

Shaperon

NCT01986933 COMPLETED

A Phase 2 Study of CIM331 for Atopic Dermatitis Patients

Chugai Pharmaceutical

NCT03901144 COMPLETED

A NOVel Moisturiser for Atopic Dermatitis: Effect on the Skin Barrier

ACO Hud Nordic AB

NCT02068352 COMPLETED

A Study to Evaluate the Effectiveness and Safety of Topical OPA-15406 Ointment to Treat Participants With Atopic Dermatitis

Otsuka Pharmaceutical Development & Commercialization, Inc.

NCT03736967 TERMINATED

Efficacy and Safety of REGN3500 Monotherapy and Combination of REGN3500 Plus Dupilumab in Adult Patients With Moderate-to-Severe Atopic Dermatitis

Regeneron Pharmaceuticals

NCT04936113 TERMINATED

Continued Safety Evaluation of FB-401 in Children, Adolescents and Adults (2 Years and Older) With Mild to Moderate Atopic Dermatitis Previously Enrolled in the FB401-01 Study

Forte Biosciences, Inc.

NCT03160248 COMPLETED

An Investigator-initiated Study of Apremilast to Demonstrate Efficacy Nummular Eczema

Technical University of Munich

NCT03517566 TERMINATED

A Study to Assess the Safety and Efficacy of ZPL389 in Patients With Moderate to Severe Atopic Dermatitis

Novartis Pharmaceuticals

NCT03948334 TERMINATED

A Study to Assess the Safety and Efficacy of ZPL389 With TCS/TCI in Atopic Dermatitis Patients

Novartis Pharmaceuticals

NCT03381625 COMPLETED

Topical Application of BMX-010 in Subjects With Atopic Dermatitis and Plaque Psoriasis

BioMimetix JV, LLC

NCT03540043 COMPLETED

Thykamine Safety and Efficacy Study in Mild-to-Moderate Atopic Dermatitis

PurGenesis Technologies Inc.

NCT04504279 COMPLETED

Evaluation of FB-401 in Children, Adolescents and Adults (2 Years and Older) With Mild to Moderate Atopic Dermatitis

Forte Biosciences, Inc.

NCT01993420 COMPLETED

A Safety and Efficacy of DRM02 in Subjects With Atopic Dermatitis

Dermira, Inc.

NCT03847389 TERMINATED

Clobetasol Topical Oil for Children With Moderate to Severe Atopic Dermatitis

Hill Dermaceuticals, Inc.

NCT04192513 TERMINATED

Observer-Blinded Dose Escalating, Single Dose to Study Safety and Antimicrobial Efficacy of Gel vs. Placebo

DermBiont, Inc.

NCT02424253 COMPLETED

A Study to Determine the Efficacy of ZPL-3893787 in Subjects With Atopic Dermatitis

Ziarco Pharma Ltd

NCT04893941 COMPLETED

Dose Escalation Trial of CM310 in Patients With Moderate-to-Severe Atopic Dermatitis (AD)

Keymed Biosciences Co.Ltd

NCT02975206 COMPLETED

Study of the Efficacy, Safety, and Tolerability of Serlopitant for Pruritus (Itch) in Atopic Dermatitis

Vyne Therapeutics Inc.

NCT03443024 COMPLETED

A Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis

Eli Lilly and Company

NCT03568136 COMPLETED

Investigation of Efficacy of Secukinumab in Patients With Moderate to Serve Atopic Dermatitis

GWT-TUD GmbH

NCT04339985 COMPLETED

Study to Evaluate Safety & Efficacy of Topical ATx201 OINTMENT in Adolescents and Adults With Mild to Moderate AD

UNION therapeutics

NCT03758716 COMPLETED

An Open-Labeled Exploratory Study to Evaluate Safety and Efficacy of FB825 in Adults With Atopic Dermatitis

Fountain Biopharma Inc.

NCT00717769 COMPLETED

A Multicenter, Randomized, Placebo-Controlled, Double-Blind Study of SUN13834 in Adult Subjects With Atopic Dermatitis

Daiichi Sankyo

NCT03831191 TERMINATED

A Study of LY3375880 in Adults With Moderate-to-Severe Atopic Dermatitis

Eli Lilly and Company

NCT04154033 WITHDRAWN

Treatment of Chronic Itch in Atopic Dermatitis With Topical Naltrexone

University of Minnesota

NCT03011892 COMPLETED

A Study to Evaluate the Safety and Efficacy of Ruxolitinib Phosphate Cream Applied Topically to Adults With Atopic Dermatitis

Incyte Corporation

NCT03903822 COMPLETED

Dose Ranging Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics of PF-06700841 Topical Cream in Participants With Mild or Moderate Atopic Dermatitis

Pfizer

NCT03496974 COMPLETED

A Phase II Study of Bermekimab (MABp1) in Patients With Moderate to Severe Atopic Dermatitis

Janssen Research & Development, LLC

NCT01756898 COMPLETED

Study to Evaluate the Efficacy, Safety and Pharmacokinetics of ASB17061 Capsules in Adult Subjects With Atopic Dermatitis

Daiichi Sankyo

NCT03808532 WITHDRAWN

Moisturizer to Prevent Atopic Dermatitis

MYOR Ltd.

NCT03864627 TERMINATED

A Study to Evaluate the Safety and Tolerability of MOR106 Administered Concomitantly With Topical Corticosteroids, in Adult Participants With Moderate to Severe Atopic Dermatitis

Galapagos NV

NCT02407756 COMPLETED

A Study to Determine the Safety and Tolerability of Dupilumab (REGN668/SAR231893) in Patients Aged ≥6 to <18 Years With Atopic Dermatitis (Eczema)

Regeneron Pharmaceuticals

NCT02144142 WITHDRAWN

Evaluation of the Kinetic Properties of an Autologous Microbiome Transplant in Adult Atopic Dermatitis Patients

University of California, San Diego

NCT03151148 COMPLETED

Targeted Microbiome Transplant in Atopic Dermatitis

National Institute of Allergy and Infectious Diseases (NIAID)

NCT02914548 COMPLETED

Study of OPA-15406 Ointment in Patients With Atopic Dermatitis

Otsuka Pharmaceutical Co., Ltd.

NCT03018691 COMPLETED

Phase 2 Study of OPA-15406 Ointment in Pediatric Patients With Atopic Dermatitis

Otsuka Pharmaceutical Co., Ltd.

NCT02925117 COMPLETED

A Study to Evaluate ABT-494 (Upadacitinib) in Adults With Moderate to Severe Atopic Dermatitis

AbbVie

NCT03954158 COMPLETED

Study to Assess Efficacy and Safety of Two Regimens of Crisaborole Ointment 2% in Japanese Participants Aged ≥2 Years With Mild to Moderate Atopic Dermatitis

Pfizer

NCT02576938 COMPLETED

A Study of Baricitinib (LY3009104) in Participants With Moderate-to-Severe Atopic Dermatitis

Eli Lilly and Company

NCT02683928 COMPLETED

To Assess the Safety and Activity of GBR 830, Compared to Placebo, in Adults With Moderate-to-severe Atopic Dermatitis

Ichnos Sciences SA

NCT02210780 COMPLETED

Study of Dupilumab and Immune Responses in Adults With Atopic Dermatitis (AD)

Regeneron Pharmaceuticals

NCT02087943 COMPLETED

Efficacy and Safety Study of Apremilast in Subjects With Moderate to Severe Atopic Dermatitis

Amgen

NCT03571620 COMPLETED

Safety and Efficacy Study of Q301 in Mild to Moderate Adolescents and Adults Atopic Dermatitis Patients

Qurient Co., Ltd.

NCT02910011 COMPLETED

Topical NanoDox® for Atopic Dermatitis

University of Florida

NCT01979016 COMPLETED

Study to Determine the Safety and Effectiveness of Dupilumab for Treatment of Atopic Dermatitis (AD)

Regeneron Pharmaceuticals

NCT03568071 TERMINATED

A Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics (PK)/Pharmacodynamics (PD) of MOR106 in Subjects With Moderate to Severe Atopic Dermatitis

Galapagos NV

NCT03055195 TERMINATED

Efficacy and Safety Study of Mepolizumab in Subjects With Moderate to Severe Atopic Dermatitis

GlaxoSmithKline

NCT03585296 COMPLETED

A Study of ATI-502 Topical Solution for the Treatment of Atopic Dermatitis

Aclaris Therapeutics, Inc.

NCT02465606 COMPLETED

A Study to Evaluate the Safety of Lebrikizumab Compared to Topical Corticosteroids in Adult Patients With Atopic Dermatitis

Hoffmann-La Roche

NCT01393158 COMPLETED

Apremilast for Atopic Dermatitis - A Pilot Study in Adults

Oregon Health and Science University

NCT03018275 COMPLETED

Beginning Assessment of Cutaneous Treatment Efficacy of Roseomonas in Atopic Dermatitis

National Institute of Allergy and Infectious Diseases (NIAID)

NCT03100344 COMPLETED

Dose-ranging Study of Nemolizumab in Atopic Dermatitis

Galderma R&D

NCT04110873 TERMINATED

A Phase II, Placebo-controlled Trial Evaluating the Efficacy of Antroquinonol in Patients With Atopic Dermatitis

Chung Shan Medical University

NCT03245385 TERMINATED

Multiple-Dose Pharmacokinetics and Potential for Adrenal Suppression Following Treatment With Halobetasol Spray in Patients With Atopic Dermatitis

Sun Pharmaceutical Industries Limited

NCT03622463 COMPLETED

A Trial of Antroquinonol in Patients With Atopic Dermatitis

Golden Biotechnology Corporation

NCT03233529 COMPLETED

Crisaborole Ointment 2% Skin Biomarker Biopsy Study in Atopic Dermatitis

Pfizer

NCT02594098 COMPLETED

Secukinumab for Treatment of Atopic Dermatitis

Icahn School of Medicine at Mount Sinai

NCT02871479 COMPLETED

A Trial of a Botanical Drug Containing East Indian Sandalwood Oil (EISO) For Treatment of Atopic Dermatitis

Santalis Pharmaceuticals, Inc.

NCT01941537 COMPLETED

Randomized Placebo Controlled Study to Determine Safety, Pharmacodynamics and Efficacy of ILV-094 in Atopic Dermatitis

Rockefeller University

NCT02780167 COMPLETED

Study To Evaluate Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis

Pfizer

NCT02795832 COMPLETED

A Study to Determine the Safety & Efficacy of ZPL-5212372 in Healthy Subjects and in Subjects With Atopic Dermatitis

Ziarco Pharma Ltd

NCT01301508 COMPLETED

Efficacy and Safety of AN2898 and AN2728 Topical Ointments to Treat Mild-to-Moderate Atopic Dermatitis

Pfizer

NCT02655679 COMPLETED

An Ascending Multiple Dose Study of VTP-38543 in Adult Participants With Mild to Moderate Atopic Dermatitis

Vitae Pharmaceuticals, Inc.

NCT03676933 COMPLETED

Efficacy and Steroid Sparing Potential Study of DGLA Cream in Early Childhood Patients With Moderate to Severe Atopic Dermatitis

DS Biopharma

NCT03134352 COMPLETED

Study to Evaluate the Efficacy and Safety of ZL-3101 in Subjects With Subacute Eczema

Zai Lab Pty. Ltd.

NCT03000595 WITHDRAWN

A Trial of a Botanical Drug Product Containing East Indian Sandalwood Oil (EISO) For Treatment of Atopic Dermatitis

Santalis Pharmaceuticals, Inc.

NCT02932891 COMPLETED

An Open Label, Safety Study to Assess the Potential for Adrenal Suppression.

Sun Pharmaceutical Industries, Inc.

NCT02595008 COMPLETED

Study to Assess the Potential for Adrenal Suppression Following Treatment With DSXS in Patients With Atopic Dermatitis

Sun Pharmaceutical Industries, Inc.

NCT01522391 COMPLETED

A Randomized, Double-blinded Placebo-controlled Study to Investigate Antimicrobial Efficacy and Safety Following Topical Application of DPK-060

DermaGen AB

NCT02748993 COMPLETED

A Study to Evaluate the Safety and Efficacy of PAC-14028 Cream in Pediatric Atopic Dermatitis

Amorepacific Corporation

NCT02945657 COMPLETED

Pharmacokinetics and Safety of MM36 Topical Ointment in Pediatric Subjects With Atopic Dermatitis

Medimetriks Pharmaceuticals, Inc

NCT03089229 COMPLETED

A Study to Evaluate the Efficacy and Safety of HAT01H in Atopic Dermatitis

Haus Bioceuticals

NCT03175354 COMPLETED

A Study in Subjects With Moderate Atopic Dermatitis

Ralexar Therapeutics, Inc.

NCT02324972 COMPLETED

Pilot Efficacy and Safety Study of AQX-1125 in Atopic Dermatitis

Aquinox Pharmaceuticals (Canada) Inc.

NCT03676036 COMPLETED

Efficacy and Steroid Sparing Potential Study of DGLA Cream in Patients With Moderate to Severe Atopic Dermatitis

DS Biopharma

NCT02004119 COMPLETED

Phase 2 Study of KHK4577

Kyowa Kirin Co., Ltd.

NCT01469767 COMPLETED

Efficacy of Fluocinonide Cream 0.1% (Vanos(R)) in Reducing Itch in Subjects With Atopic Dermatitis

Wake Forest University

NCT01471119 COMPLETED

Sublingual Immunotherapy in Patients With Atopic Dermatitis

Zhejiang University

NCT01548404 COMPLETED

Study of Dupilumab in Adult Patients With Extrinsic Moderate-to-Severe Atopic Dermatitis

Regeneron Pharmaceuticals

NCT02950922 COMPLETED

Study of RVT-501 in Adult and Adolescent Subjects With Atopic Dermatitis

Dermavant Sciences GmbH

NCT03394677 COMPLETED

Study of RVT-501 Topical Ointment in Pediatric Patients With Atopic Dermatitis

Dermavant Sciences GmbH

NCT02347176 COMPLETED

Phase 2 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults With Atopic Dermatitis

MedImmune LLC

NCT03464526 WITHDRAWN

A Study of the Efficacy and Safety of Orvepitant in Subjects With Pruritus Associated With Atopic Dermatitis

Nerre Therapeutics Ltd.

NCT00703573 COMPLETED

A Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of 2 Doses of S-777469 in Patients With Atopic Dermatitis

Shionogi

NCT02949960 COMPLETED

DMT210 Topical Gel in the Treatment of Atopic Dermatitis

Dermata Therapeutics

NCT02865356 COMPLETED

Topical Solution for the Treatment of Atopic Dermatitis

Spherium Biomed

NCT02002208 COMPLETED

Effect of OC000459 on Moderate to Severe Atopic Dermatitis

Atopix Therapeutics, Ltd.

NCT03304470 COMPLETED

A Study to Evaluate the Safety and Efficacy of ATx201 in Subjects With Moderate Atopic Dermatitis

UNION therapeutics

NCT01806662 COMPLETED

Pilot Study of Ustekinumab for Subjects With Chronic Atopic Dermatitis

Rockefeller University

NCT02525094 COMPLETED

Phase 2a Study to Evaluate the Efficacy and Safety of MEDI9929 in Adults With Atopic Dermatitis

MedImmune LLC

NCT03091426 COMPLETED

Pharmacodynamics of Omiganan BID in Patients With Atopic Dermatitis

Maruho Co., Ltd.

NCT02475447 COMPLETED

Safety, Pharmacokinetics and Preliminary Efficacy of Asimadoline in Pruritus Associated With Atopic Dermatitis

Tioga Pharmaceuticals

NCT02564055 COMPLETED

A Dose-Finding Study of GSK2894512 Cream in Subjects With Atopic Dermatitis (AD)

GlaxoSmithKline

NCT01299610 COMPLETED

A Study to Test the Effect of 2 Different Doses of Topical GW870086X on Atopic Dermatitis Also Including a Postive Control and a Placebo

GlaxoSmithKline

NCT01639040 COMPLETED

Study to Assess the Safety of Dupilumab (REGN668/SAR231893) Administered Concomitantly With Topical Corticosteroids (TCS) in Patients With Moderate-to-severe Atopic Dermatitis (AD)

Regeneron Pharmaceuticals

NCT02340234 COMPLETED

A Study of Lebrikizumab in Participants With Persistent Moderate to Severe Atopic Dermatitis

Hoffmann-La Roche

NCT01859988 COMPLETED

Study of Dupilumab Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis

Regeneron Pharmaceuticals

NCT02900131 COMPLETED

Efficacy, Safety and Dose Finding Trial of Topical Jaungo Application in Atopic Dermatitis Patients

Kyung Hee University Hospital at Gangdong

NCT01652885 COMPLETED

Safety, Tolerability, and PK of AN2728 in Adolescents With Atopic Dermatitis

Pfizer

NCT00789880 COMPLETED

Analysis of Response of Subjects With Atopic Dermatitis or Psoriasis to Oral Vitamin D3

National Institute of Allergy and Infectious Diseases (NIAID)

NCT01033097 COMPLETED

Safety and Efficacy of DNK333 in Atopic Dermatitis Patients

Novartis Pharmaceuticals

NCT01366846 COMPLETED

Persistence of Oral Tolerance to Peanut

National Institute of Allergy and Infectious Diseases (NIAID)

NCT01602341 COMPLETED

Efficacy and Safety of AN2728 Topical Ointment to Treat Adolescents With Atopic Dermatitis

Pfizer

NCT02691507 COMPLETED

Trial to Determine the Therapeutic Benefit of an OTC Cream on Dry, Itchy Skin of Adults and Children With Eczema

Johnson & Johnson Consumer Inc. (J&JCI)

NCT03059693 COMPLETED

Efficacy and Tolerability of HAT1 in Patients With Moderate to Severe Atopic Dermatitis

Haus Bioceuticals

NCT01552629 COMPLETED

A Study Evaluating the Safety and Efficacy of QGE031 in Atopic Dermatitis Patients

Novartis Pharmaceuticals

NCT02669888 COMPLETED

Indigo Naturalis in Treating Atopic Dermatitis Topically

Chang Gung Memorial Hospital

NCT01856764 COMPLETED

Topical Roflumilast in Adults With Atopic Dermatitis

AstraZeneca

NCT02079688 COMPLETED

Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of the Topical Formulation SB011 Applied to Lesional Skin in Patients With Atopic Eczema

Sterna Biologicals GmbH & Co. KG

NCT02426359 COMPLETED

Safety and Efficacy Study of Q301 in Moderate to Severe Atopic Dermatitis Patients

Qurient Co., Ltd.

NCT01927705 COMPLETED

Safety and Efficacy of FURESTEM-AD Inj. in Patients With Moderately Subacute and Chronic Atopic Dermatitis (AD)

Kang Stem Biotech Co., Ltd.

NCT02757729 COMPLETED

A Study to Evaluate the Safety and Efficacy of PAC-14028 Cream in Adults With Atopic Dermatitis

Amorepacific Corporation

NCT02456480 COMPLETED

Pharmacodynamics of Omiganan (CLS001) in Patients With Atopic Dermatitis

Maruho Co., Ltd.

NCT01254240 COMPLETED

Efficacy Study of Two Choices of Phototherapy on Itching Skin Diseases

University of Zurich

NCT02031445 TERMINATED

Double-Blind, Trial to Evaluate the Safety and Efficacy of MRX-6 Cream 2%

Celsus Therapeutics PLC

NCT01945086 COMPLETED

A Study of Ustekinumab (STELARA®) in Adult Japanese Participants With Severe Atopic Dermatitis

Janssen Pharmaceutical K.K.

NCT01228513 COMPLETED

Efficacy and Safety of Different Concentrations of ZK245186 in Atopic Dermatitis (AD)

Bayer

NCT01785602 COMPLETED

Efficacy and Safety Study of QAW039 in the Treatment of Patients With Moderate to Severe Atopic Dermatitis.

Novartis Pharmaceuticals

NCT02379910 COMPLETED

A Study to Assess the Safety, Tolerability, PK and PD of AM1030-CREAM in Patients With Atopic Dermatitis

AnaMar AB

NCT01497119 TERMINATED

A Study of JNJ-39758979 in Adult Japanese Patients With Moderate Atopic Dermatitis

Janssen Pharmaceutical K.K.

NCT01808157 COMPLETED

A Study to Evaluate the Efficacy, Safety and Tolerability of CT327 in Atopic Dermatitis

Creabilis SA

NCT02583022 COMPLETED

A Study to Evaluate the Safety and Efficacy of PAC-14028 Cream in Atopic Dermatitis

Amorepacific Corporation

NCT02001181 COMPLETED

Tofacitinib Ointment For Atopic Dermatitis (Atopic Eczema)

Pfizer

NCT01792713 COMPLETED

Sertaconazole 2% Cream to Improve Symptoms Associated With Atopic Dermatitis

Spirig Pharma Ltd.

NCT01359787 COMPLETED

Efficacy and Safety of Different Concentrations of Mapracorat Ointment Over 4 Weeks in Atopic Dermatitis (AD)

Bayer

NCT01597817 COMPLETED

Efficacy and Safety of a a Biofunctional Textile in the Management of Atopic Dermatitis

Universidade do Porto

NCT00927212 TERMINATED

Topical Application of AS101 for the Treatment of Atopic Dermatitis

BioMAS Ltd

NCT01826461 COMPLETED

An Evaluation of PDI-192 0.1% in Comparison to PDI-192 0.15% in the Treatment of Mild to Moderate Atopic Dermatitis

PreCision Dermatology, Inc.

NCT00980135 COMPLETED

Sinecort Pilot Efficacy Study

Bayer

NCT00723489 COMPLETED

Immune Response to Yellow Fever Vaccination in Adults With Atopic Dermatitis

National Institute of Allergy and Infectious Diseases (NIAID)

NCT01605708 TERMINATED

Study to Assess the Clinical Activity of a Sequential Dose of REGN846 on Refractory Pruritus in Patients With Atopic Dermatitis

Regeneron Pharmaceuticals

NCT01902836 COMPLETED

Efficacy Study of Dialyzed Leukocytes Extracts to Treat Paediatric Moderate Atopic Dermatitis

National Polytechnic Institute, Mexico

NCT01320579 COMPLETED

Investigation of the Efficacy of 2.5% and 5% Cis-urocanic Acid in Patients With Moderate or Severe Atopic Dermatitis

BioCis Pharma Ltd

NCT01232985 COMPLETED

Efficacy and Tolerability Study of Device, RD047-26 for the Treatment of Mild to Moderate Atopic Dermatitis in Adults

Oculus Innovative Sciences, Inc.

NCT01232543 COMPLETED

Safety Study Evaluating the Adrenal Suppression Potential of Product 0405 in Pediatric Subjects With Atopic Dermatitis

Fougera Pharmaceuticals Inc.

NCT00932074 COMPLETED

A Study to Determine the Safety, Tolerability and Efficacy of KP-413 in Subjects With Atopic Dermatitis(AD)

Kaken Pharmaceutical

NCT00914186 COMPLETED

Study of TS-022 in Adult Patients With Atopic Dermatitis With Pruritus (POC)

Taisho Pharmaceutical R&D Inc.

NCT01098734 COMPLETED

Non-steroid, Atopic Dermatitis Phase IIb 12-week Trial; Topical WBI-1001 Cream

Welichem Biotech Inc.

NCT00991198 COMPLETED

The Role of Topically Dissolved Oxygen (TDO) to Ameliorate Signs of Photodamage

Aria Aesthetics Inc.

NCT01223222 COMPLETED

A Study to Evaluate Safety, Tolerability and Efficacy of Lytixar™ (LTX-109) on Uncomplicated, Gram-positive, Skin Infection

Lytix Biopharma AS

NCT00931242 COMPLETED

Study of Apremilast in Atopic or Contact Dermatitis

Tufts Medical Center

NCT00980629 COMPLETED

Dose-Finding Study of M516102 in the Treatment of Pruritus Associated With Atopic Dermatitis

Maruho Co., Ltd.

NCT00996008 TERMINATED

CT 327 in the Treatment of Atopic Dermatitis

Creabilis SA

NCT00883311 COMPLETED

A Study of BRT-FC-83C for the Treatment of Atopic Dermatitis

Biomed Research & Technologies, Inc.

NCT01119313 COMPLETED

Study to Investigate Skin Conditions and Patient Assessment of LAS 41002 in the Treatment of Atopic Eczema

Almirall, S.A.

NCT01020994 COMPLETED

Efficacy and Safety of LAS41003 in the Treatment of Superficial Infected Eczema

Almirall, S.A.

NCT00882245 COMPLETED

Safety and Efficacy of SRD441 Ointment in Patients With Atopic Dermatitis

Serentis Ltd.

NCT00838708 COMPLETED

Phase IIa Safety and Efficacy Study of SRD174 Cream in Patients With AD-associated Pruritus

Serentis Ltd.

NCT00690807 COMPLETED

A Phase 2 Study of PH-10 for the Treatment of Atopic Dermatitis

Provectus Pharmaceuticals

NCT00837551 COMPLETED

Phase IIa Study of WBI-1001 Cream for Atopic Dermatitis

Welichem Biotech Inc.

NCT07262983 RECRUITING

Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopic Dermatitis

National Institute of Allergy and Infectious Diseases (NIAID)

NCT07488065 RECRUITING

A Study of SKB575 (HBM7575) Injection in Healthy Participants and Atopic Dermatitis Participants

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

NCT06928246 RECRUITING

The Impact of Botox on Neuroimmune Interactions in Atopic Dermatitis

Daniel Kaplan

NCT07558668 RECRUITING

A 3-part Study of SYX-5219 in Healthy Volunteers and Participants With Atopic Dermatitis

Sitryx Therapeutics Ltd

NCT07264335 ACTIVE NOT RECRUITING

A Study on the Bioavailability of SHR-1819 Injection Administered Subcutaneously Using Different Injection Devices in Healthy Subjects

Guangdong Hengrui Pharmaceutical Co., Ltd

NCT07549984 NOT YET RECRUITING

A Study of IBI3033 in Moderate-to-Severe Atopic Dermatitis

Innovent Biologics (Suzhou) Co. Ltd.

NCT07549750 NOT YET RECRUITING

A Dose Escalation Phase 1 Study of HXN5003 in Healthy Participants

Helixon Biotechnology (Suzhou) Co., Ltd

NCT07411755 RECRUITING

A Phase 1 Clinical Study Comparing GS101 and Dupixent® After Subcutaneous Injection

Jiangsu Genscend Biopharmaceutical Co., Ltd

NCT06342713 RECRUITING

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single- and Multiple-Ascending Doses and Food Effect of BGB-45035 in Healthy Participants and in Adults With Autoimmune Dermatological Diseases

BeiGene

NCT07533851 NOT YET RECRUITING

A Food Effect Study of VC005 Tablets in Healthy Adult Subjects.

Jiangsu vcare pharmaceutical technology co., LTD

NCT07527923 NOT YET RECRUITING

First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic Dermatitis

Regeneron Pharmaceuticals

NCT07146971 RECRUITING

Clinical Evaluation of Skin Microbiome an Over-The-Counter (OTC) Drug for Atopic Dermatitis

Good Molecules, LLC

NCT06564389 RECRUITING

FIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients

Pfizer

NCT07027527 ACTIVE NOT RECRUITING

An Active Comparator Safety Study Evaluating the Combination of APG777 + APG990 in Moderate-to-Severe Atopic Dermatitis

Apogee Therapeutics, Inc.

NCT06504160 RECRUITING

Targeted Investigation of Microbiome 2 Treat Atopic Dermatitis (TIME-2)

National Institute of Allergy and Infectious Diseases (NIAID)

NCT07453602 RECRUITING

Ph 1a/1b Single Ascending Dose and Multiple Ascending Dose Study of ARQ-234

Arcutis Biotherapeutics, Inc.

NCT07455578 NOT YET RECRUITING

Study of S-4321 in Participants With an Autoimmune or Immune-mediated Disease

Seismic Therapeutic AU Pty Ltd

NCT06787586 ACTIVE NOT RECRUITING

Safety, Tolerability and PK of ATTO-1310 in Healthy Volunteers and Patients With Atopic Dermatitis and Patients With Chronic Pruritus

Attovia Therapeutics Inc

NCT06934252 RECRUITING

Phase 1a/1b Study of TRB-061 in Healthy Participants & Atopic Dermatitis Patients

TRex Bio, Inc.

NCT07358156 RECRUITING

A Study to Compare the Pharmacokinetics, Pharmacodynamic, Immunogenicity, and Safety of CKD-706 With US-Dupixent®, and EU-Dupixent® in Healthy Adult Participants.

Chong Kun Dang Pharmaceutical

NCT06982352 RECRUITING

Safety and Pharmacokinetics of LPX-TI641 in Atopic Dermatitis and Psoriasis

LAPIX Therapeutics Inc.

NCT07235384 RECRUITING

A Phase 1/1b Study to Evaluate Safety, Tolerability and Pharmacokinetics of ZL-1503 in Healthy Volunteers and Participants With Moderate to Severe Atopic Dermatitis

Zai Lab (Shanghai) Co., Ltd.

NCT07190430 ACTIVE NOT RECRUITING

A Study to Learn If the Study Medicine Called PF-08049820 Changes How the Body Processes the Other Study Medicines Called Oral Contraceptives, Midazolam, and Dabigatran in Healthy Adult Female Participants

Pfizer

NCT06920693 ACTIVE NOT RECRUITING

Study to Investigate the Safety, Tolerability, and Pharmacokinetics of GB-7624 in Healthy Adult Participants

Generate Biomedicines

NCT07205081 RECRUITING

Safety, Tolerability and PK of ATTO-3712 in Healthy Volunteers and Patients With Atopic Dermatitis

Attovia Therapeutics Inc

NCT06744569 ENROLLING BY INVITATION

A Phase I Clinical Trial to Evaluate CU-10101 Unguent

Cutia Therapeutics（Wuxi）Co.,Ltd

NCT07239947 RECRUITING

A Study of BBT001 in Healthy Volunteers (HVs) and in Adult Patients With Moderate to Severe Atopic Dermatitis (AD)

Bambusa Therapeutics

NCT06808477 RECRUITING

A Study of BBT001 in Healthy Volunteers (HVs) and in Adult Patients With Atopic Dermatitis (AD)

Bambusa Therapeutics

NCT06055361 RECRUITING

A Study to Investigate the Safety, Tolerability, and Efficacy of BxC-I17e Single and Multiple Dose SC Injection in Patients With Moderate to Severe Atopic Dermatitis

Brexogen Inc.

NCT07015762 RECRUITING

A Study to Evaluate the Safety and Tolerability of Multiple Dose of IBI3002 in Patients With Atopic Dermatitis

The First Affiliated Hospital of Soochow University

NCT06946641 RECRUITING

A Phase I Study of QLS12010 Capsules: Safety, Tolerability, PK, PD, and Food Effects in Healthy Adults and Moderate to Severe Atopic Dermatitis Patients

Shanghai Qilu Pharmaceutical Research and Development Center LTD

NCT07042113 NOT YET RECRUITING

A Study of Two Different Formulations of 611 in Healthy Adult Subjects in China

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

NCT00798226 ACTIVE NOT RECRUITING

Fish Oil Supplementation During Pregnancy for Prevention of Asthma, Eczema and Allergies in Childhood

Copenhagen Studies on Asthma in Childhood

NCT06082323 RECRUITING

A Single and Multiple Ascending Dose Trial of LT-002-158 Tablets in Healthy Adult Volunteers

Leadingtac Pharmaceutical (Shaoxing) Co., Ltd.

NCT05859724 TERMINATED

Evaluation of NM26-2198 in Healthy Subjects and in Patients With Moderate-to-severe Atopic Dermatitis (AD)

Yellow Jersey Therapeutics AG

NCT07329101 COMPLETED

Clinical Study to Evaluate the Safety, Pharmacokinetics and Efficacy of VC005 in Adolescent Subjects With Mild to Moderate Atopic Dermatitis

Jiangsu vcare pharmaceutical technology co., LTD

NCT07466940 COMPLETED

A Clinical Study to Evaluate SM17 in Healthy Participants

SinoMab BioScience Ltd

NCT07336940 COMPLETED

Study of ENV-294 in Healthy Adults and in Adults With Moderate-to-Severe Atopic Dermatitis

Enveda Therapeutics

NCT06345404 COMPLETED

Safety, Tolerability, and Preliminary Efficacy of Soquelitinib in Participants With Moderate to Severe AD

Corvus Pharmaceuticals, Inc.

NCT06945458 COMPLETED

Safety, PK, PD, and Clinical Activity of Orally Administered KT-621 in Adult Patients With Atopic Dermatitis (AD)

Kymera Therapeutics, Inc.

NCT06438263 COMPLETED

A Study to Evaluate Bioavailability of Rocatinlimab Autoinjector and Vial in Healthy Participants

Amgen

NCT06214481 COMPLETED

A Study to Evaluate Rocatinlimab (AMG 451) in Healthy Chinese Participants

Amgen

NCT06268860 COMPLETED

A Study to Assess Bioavailability of Rocatinlimab (AMG 451) Vial and Prefilled Syringe in Healthy Participants

Amgen

NCT05288543 TERMINATED

A Study of Orally Administered IPG7236 in Healthy Adult Participants

Nanjing Immunophage Biotech Co., Ltd

NCT05803902 COMPLETED

An Evaluation of 9MW1911 Injection in Healthy Subjects

Mabwell (Shanghai) Bioscience Co., Ltd.

NCT06248814 COMPLETED

A Study to Evaluate the Safety, Tolerability, Drug Levels, and Drug Effects of BMS-986326 in Participants With Atopic Dermatitis

Bristol-Myers Squibb

NCT06005792 TERMINATED

Multiple Ascending-Dose Study of XmAb®27564 in Patients With Psoriasis or Atopic Dermatitis

Xencor, Inc.

NCT07172321 COMPLETED

A Study to Learn How Different Forms of the Study Medicine Called PF 08049820 Are Taken up Into the Bloodstream in Healthy Adults

Pfizer

NCT06119529 TERMINATED

A Study of LY3872386 in Healthy Participants and Participants With Atopic Dermatitis

Eli Lilly and Company

NCT06553209 COMPLETED

Study of CM512 in Healthy Subjects and Patients With Atopic Dermatitis

Keymed Biosciences Co.Ltd

NCT05114889 COMPLETED

Safety and Tolerability of BSI-045B in Healthy Adult Subjects and Patients With Atopic Dermatitis

Biosion, Inc.

NCT06193434 COMPLETED

A First In Human (FIH) Study of IBI356 in Healthy Participants and in Atopic Dermatitis Patients

Innovent Biologics (Suzhou) Co. Ltd.

NCT04975438 COMPLETED

Clinical Effect, Safety and Tolerability of GSK1070806 in Atopic Dermatitis

GlaxoSmithKline

NCT06469385 TERMINATED

Topical ENS-002 for Atopic Dermatitis in Adults

Concerto Biosciences

NCT07113366 COMPLETED

Efficacy of Jelly Fig (Ficus Awkeotsang Makino) Extract for Atopic Dermatitis

Kaohsiung Veterans General Hospital.

NCT07103369 COMPLETED

A Phase I Clinical Study to Evaluate SM17 in Chinese Healthy Subjects and Patients With Moderate to Severe Atopic Dermatitis

SinoMab BioScience Ltd

NCT06974292 COMPLETED

The Mass Balance and Biotransformation Study of [14C] VC005 in Chinese Healthy Adult Male Volunteers

Jiangsu vcare pharmaceutical technology co., LTD

NCT03250663 COMPLETED

Eucrisa for Atopic Dermatitis

Wake Forest University Health Sciences

NCT05450198 COMPLETED

Multiple Rising Dose Study of MK-6194 in Participants With Atopic Dermatitis (MK-6194-008)

Merck Sharp & Dohme LLC

NCT05486117 COMPLETED

Pharmacokinetics of Delgocitinib 20 mg/g Cream in Subjects With Chronic Hand Eczema

LEO Pharma

NCT06614907 COMPLETED

A PhaseⅠ Comparative Study to Evaluate the Pharmacokinetics of QL2108 to Dupixent®

Qilu Pharmaceutical Co., Ltd.

NCT02376049 COMPLETED

A Clinical Trial to Compare Topical Agents in Adults With Mild to Moderate Atopic Dermatitis (AD)

LEO Pharma

NCT02219633 COMPLETED

Effect of LEO 39652 Cream in Adults With Mild to Moderate Atopic Dermatitis (AD)

LEO Pharma

NCT00891709 COMPLETED

LEO 29102 Single and Multiple Dose Study by Dermal Application

LEO Pharma

NCT03514511 COMPLETED

Safety and Tolerability of LEO 138559 in Healthy Subjects and Subjects With Atopic Dermatitis

LEO Pharma

NCT01423656 COMPLETED

Safety, Tolerability and Pharmacokinetic Study in Healthy Subjects by Dermal Application of a LEO 29102

LEO Pharma

NCT01850849 COMPLETED

Safety, Tolerability and Pharmacokinetics in AD Subjects and Healthy Subjects of Cutaneous Application of LEO 39652 Cream

LEO Pharma

NCT01005823 COMPLETED

A Safety, Tolerability and Pharmacokinetic Study of LEO 29102 in Subjects With Atopic Dermatitis

LEO Pharma

NCT03556592 COMPLETED

Drug-drug Interaction Trial With Tralokinumab in Moderate to Severe Atopic Dermatitis - ECZTRA 4

LEO Pharma

NCT02103725 COMPLETED

A Multi-Centre Clinical Trial to Evaluate a Left-Right Design in Adults With Mild to Moderate Atopic Dermatitis

LEO Pharma

NCT03826901 COMPLETED

Delgocitinib Cream for the Treatment of Moderate to Severe Atopic Dermatitis During 8 Weeks in Adults, Adolescents, and Children

LEO Pharma

NCT01447758 TERMINATED

Safety, Tolerability and Pharmacokinetics of LEO 29102 Cream in Atopic Dermatitis.

LEO Pharma

NCT00958516 COMPLETED

Assessment of the Phototoxic Potential of LEO 29102 Cream

LEO Pharma

NCT05099133 COMPLETED

A Trial to Evaluate Pharmacokinetics, Immunogenicity, Safety, and Tolerability of LEO 138559 in Healthy Japanese Subjects

LEO Pharma

NCT03646604 COMPLETED

A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Upadacitinib in Pediatric Participants With Severe Atopic Dermatitis

AbbVie

NCT06009094 COMPLETED

Safety, Tolerance and Pharmacokinetics Clinical Study of VC005 in Healthy Subjects and Patients with Mild to Moderate Atopic Dermatitis

Jiangsu vcare pharmaceutical technology co., LTD

NCT05177328 TERMINATED

Targeted Investigation of Microbiome Elimination

National Institute of Allergy and Infectious Diseases (NIAID)

NCT06673654 COMPLETED

A Study, Comparing Ruxolitinib Topical Cream 1.5% (Taro Pharmaceuticals U.S.A, Inc.) to OPZELURA (Ruxolitinib) Cream for the Treatment of Mild-to-Moderate Atopic Dermatitis.

Sun Pharmaceutical Industries, Inc.

NCT06553287 COMPLETED

Safety, Tolerability and Pharmacokinetics of LNK01004 Ointment in Adults With Atopic Dermatitis.

Lynk Pharmaceuticals Co., Ltd

NCT05590338 COMPLETED

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic of GSK1070806 After a Single Intravenous Dose in Healthy Male and Female Caucasian, Chinese and Japanese Participants Aged 18 to 65 Years of Age Inclusive

GlaxoSmithKline

NCT06055374 WITHDRAWN

A Study to Investigate the Safety, Tolerability, and Efficacy of BxC-I17e Repeated-dose SC Injection in Patients With Moderate to Severe Atopic Dermatitis

Brexogen Inc.

NCT03775434 COMPLETED

A Study of B244 Delivered as a Topical Spray to Assess Safety in Pediatric Subjects With Atopic Dermatitis

AOBiome LLC

NCT04668066 COMPLETED

Study to Evaluate Safety and Tolerability of PF-07242813 in Healthy Participants and Participants With Atopic Dermatitis

Pfizer

NCT05486208 TERMINATED

A Study of LY3844583 in Healthy Participants and Participants With Atopic Dermatitis

Eli Lilly and Company

NCT05945810 COMPLETED

Evaluation of TLL-018 Extended and Immediate Release Formulation for Bioequivalence Testing in Healthy Chinese Subjects

Hangzhou Highlightll Pharmaceutical Co., Ltd

NCT04081350 COMPLETED

A Study of LY3471851 in Participants With Eczema

Nektar Therapeutics

NCT05718921 COMPLETED

A Safety, Tolerability and Pharmacokinetics Study of Topical Ointment YR001 in Adult Healthy Volunteers

Hangzhou Yirui Pharmaceutical Technology Co., Ltd

NCT05170243 COMPLETED

A Clinical Study in Healthy Subjects to Evaluate 9MW1911 Injection

Mabwell (Shanghai) Bioscience Co., Ltd.

NCT05383378 COMPLETED

A First-In-Human Study to Evaluate the Safety, Tolerability, and Efficacy of Si-544 in Adults With Atopic Dermatitis

selectION Therapeutics GmbH

NCT05932888 COMPLETED

Safety, Tolerability, and Pharmacokinetic Study of QLM3003 in Healthy Adult Subjects

Qilu Pharmaceutical Co., Ltd.

NCT05034822 COMPLETED

Study of Ruxolitinib Cream in Children With Atopic Dermatitis

Incyte Corporation

NCT05382819 TERMINATED

A Safety, Tolerability and Preliminary Efficacy Study of FRTX-02 Capsules in Healthy Subjects and Subjects With Atopic Dermatitis

Fresh Tracks Therapeutics, Inc.

NCT04156191 COMPLETED

Pharmacokinetics (PK), Safety, Efficacy and Maximal Use PK of ARQ-151 in Adolescents/Children With Mild/Moderate Eczema

Arcutis Biotherapeutics, Inc.

NCT03139981 COMPLETED

A Study To Evaluate ASN002 In Subjects With Atopic Dermatitis

Asana BioSciences

NCT03798561 COMPLETED

Study to Evaluate ASN008 Topical Gel (TG)

Asana BioSciences

NCT05461456 COMPLETED

Bioavailability and Tolerability of Fexofenadine Hydrochloride Topical Lotion 1%

OrchestratePharma GmbH

NCT02590289 COMPLETED

A Pharmacokinetic Study to Evaluate BBI-5000 Capsules and Food Effect in Healthy Adult Subjects

Fresh Tracks Therapeutics, Inc.

NCT05638165 COMPLETED

A Single-center, Randomized, Double-blinded, Placebo-controlled, Phase 1 Clinical Trial to Evaluate the Safety, Tolerability and Efficacy of NCP112

NovaCell Technology Inc.

NCT04544943 COMPLETED

Safety, Tolerability, Pharmacokinetics and Efficacy of Twice Daily Application of Topical BioLexa in Adult Healthy Subjects and Patients With Mild to Moderate Atopic Dermatitis

Hoth Therapeutics, Inc.

NCT04612062 COMPLETED

A First-in-Human Study of CEE321 in Adult Subjects

Novartis Pharmaceuticals

NCT04772885 COMPLETED

A Single and Multiple Ascending Dose Trial of KT-474 in Healthy Adult Volunteers and Patients With Atopic Dermatitis (AD) or Hidradenitis Suppurativa (HS)

Kymera Therapeutics, Inc.

NCT04927195 COMPLETED

Study in Healthy Participants and Participants With Moderate Atopic Dermatitis & Optionally, Moderate Psoriasis, and/or Mild Asthma

Evelo Biosciences, Inc.

NCT00757042 COMPLETED

Safety Study of Tezepelumab (AMG 157) in Healthy Adults and Adults With Atopic Dermatitis

Amgen

NCT04256174 COMPLETED

A Study of AK120 (IL-4Rα) in Healthy Subjects and Subjects With Moderate- to- Severe Atopic Dermatitis

Akesobio Australia Pty Ltd

NCT02743871 COMPLETED

Study Of PF-06817024 In Healthy Subjects, In Patients With Chronic Rhinosinusitis With Nasal Polyps And in Patients With Atopic Dermatitis

Pfizer

NCT04262791 TERMINATED

A Non-Drug Study Detecting And Quantifying Nocturnal Scratch Behaviors From Wrist Actigraphy Data In Adult Healthy Volunteers And Participants With Atopic Dermatitis (AD)

AbbVie

NCT04090229 COMPLETED

A Multi-center, Randomized, Double-blind, Placebo-controlled, Multiple Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of Subcutaneously Delivered ASLAN004 in Adults With Moderate-Severe Atopic Dermatitis

ASLAN Pharmaceuticals

NCT03733353 COMPLETED

A Study of EDP1815 in Healthy Participants and Participants With Mild to Moderate Psoriasis and Atopic Dermatitis

Evelo Biosciences, Inc.

NCT03542994 COMPLETED

A Study of EDP1066 in Healthy Participants and Participants With Mild to Moderate Psoriasis and Atopic Dermatitis

Evelo Biosciences, Inc.

NCT03750643 COMPLETED

A Study of LY3454738 in Healthy Participants and Participants With Atopic Dermatitis

Eli Lilly and Company

NCT04271514 COMPLETED

A First-in-Human Study of RPT193 in Healthy Volunteers and Patients With Atopic Dermatitis

RAPT Therapeutics, Inc.

NCT03663673 COMPLETED

Effect of Different Skin Creams on TEWL

Stanford University

NCT04056130 COMPLETED

A Study of Single and Multiple Ascending Doses of KBL697 in Healthy Subjects

KoBioLabs

NCT04211415 TERMINATED

Phase I Study of DS-2741a in Healthy Volunteers and Participants With Atopic Dermatitis

Daiichi Sankyo Co., Ltd.

NCT03492398 COMPLETED

A Phase I Study of HY209 Gel in Healthy Male Volunteers for Atopic Dermatitis

Shaperon

NCT01428297 COMPLETED

A Study Evaluating the Safety and Efficacy of Topical BPR277 for the Treatment of Atopic Dermatitis and Netherton Syndrome

Novartis Pharmaceuticals

NCT02345928 COMPLETED

A Single Ascending Dose Study in Healthy Participants and Multiple Ascending Dose Study of CNTO 7160 in Participants With Asthma and Participants With Atopic Dermatitis

Janssen Research & Development, LLC

NCT03257644 COMPLETED

A Pharmacokinetic Study of Ruxolitinib Phosphate Cream in Pediatric Subjects With Atopic Dermatitis

Incyte Corporation

NCT01960764 WITHDRAWN

Examination of Whether Host Preconditioning Modifies Short-term Transplant Survival

University of California, San Diego

NCT01959113 COMPLETED

Validation of the Short-term Antimicrobial Action of Transplanted Bacteria

University of California, San Diego

NCT03689829 TERMINATED

A Study to Test Safety, Tolerability, and the Way the Body Absorbs, Distributes, and Gets Rid of a Study Drug Called MOR106, in Healthy Subjects and in Patients With Moderate to Severe Atopic Dermatitis

Galapagos NV

NCT01385657 COMPLETED

Safety and Tolerability of Dupilumab in Participants With Moderate to Severe Atopic Dermatitis

Regeneron Pharmaceuticals

NCT03920852 COMPLETED

A Maximum Use Trial of Ruxolitinib Cream in Adolescent and Adult Participants With Atopic Dermatitis

Incyte Corporation

NCT03846466 TERMINATED

Study of KHK 4323 in Healthy Volunteers and Subjects With Atopic Dermatitis

Kyowa Kirin Co., Ltd.

NCT04065633 COMPLETED

Study of Commercial and Phase 3 of PF-04965842 Formulations, Estimation of Effect of Food on Commercial Formulation

Pfizer

NCT01122914 TERMINATED

A Pilot Study Using Anakinra/Kineret for the Treatment of Patients With Severe Atopic Dermatitis

National Institute of Allergy and Infectious Diseases (NIAID)

NCT02286999 WITHDRAWN

Probiotic Supplementation in Breastfed Newborn Infants

Emanual Maverakis, MD

NCT03158012 COMPLETED

Evaluation of the Efficacy of an Autologous Microbiome Transplant in Adult Atopic Dermatitis Patients

University of California, San Diego

NCT01732510 TERMINATED

A Study of Intravenous MK-8226 in Participants With Moderate-to-Severe Atopic Dermatitis (MK-8226-003)

Merck Sharp & Dohme LLC

NCT03260595 COMPLETED

A Study of Crisaborole Ointment 2% in Adult Japanese Healthy Subjects and Adult Japanese Subjects With Mild To Moderate Atopic Dermatitis

Pfizer

NCT03634345 COMPLETED

Drug Drug Interaction Study Evaluating the Effect of Fluvoxamine or Fluconazole on PK and Safety of PF-04965842.

Pfizer

NCT03431610 COMPLETED

A Phase 1b Study Assessing the PK, PD, Safety & Tolerability of SB414 in Atopic Dermatitis

Novan, Inc.

NCT03050151 COMPLETED

Study of Dupilumab Auto-injector Device When Used by Patients With Atopic Dermatitis

Regeneron Pharmaceuticals

NCT03096223 COMPLETED

A Phase 1 Study of KHK4083 in Subjects With Atopic Dermatitis

Kyowa Kirin Co., Ltd.

NCT02888704 COMPLETED

Safety and Efficacy of ADSTEM Inj. in Patients With Moderately Subacute and Chronic Atopic Dermatitis

EHL Bio Co., Ltd.

NCT02739009 COMPLETED

First in Human of Single and Multiple Doses of MOR106

Galapagos NV

NCT01381445 COMPLETED

A Study Assessing GW870086's Potential to Cause Skin Thinning

GlaxoSmithKline

NCT02637206 COMPLETED

Skin Irritation Study of GSK2894512 Cream

GlaxoSmithKline

NCT01673529 COMPLETED

Investigation of Topical SB705498 on Healthy Volunteers

GlaxoSmithKline

NCT02466152 COMPLETED

Pharmacokinetic Study of Topical GSK2894512 Cream

GlaxoSmithKline

NCT02411162 COMPLETED

A Single Dose Phase I Exploratory Study in Healthy Volunteers With GSK2894512 Cream

Stiefel, a GSK Company

NCT02496546 COMPLETED

An Explorative Trial Evaluating the Effect of LEO 32731 Cream in Adults With Mild to Moderate Atopic Dermatitis (AD)

LEO Pharma

NCT02148744 COMPLETED

Safety and Tolerability of XmAb®7195 in Adult Healthy Volunteers and Adult Subjects With a History of Allergic Rhinitis and/or Allergic Conjunctivitis and/or Atopic Dermatitis

Xencor, Inc.

NCT02334787 COMPLETED

A Phase 1 Trial of OPA-15406 Ointment in Healthy Adult Male Subjects

Otsuka Pharmaceutical Co., Ltd.

NCT02647086 COMPLETED

Open Label, Drug-Drug Interaction (DDI) Study of Dupilumab (REGN668/SAR231893) in Patients With Moderate to Severe Atopic Dermatitis (AD)

Regeneron Pharmaceuticals

NCT02620293 COMPLETED

A 47 Hour Occlusive Cutaneous Skin Patch Test on Adult Subjects With Dry/Atopic Skin

Reckitt Benckiser Healthcare (UK) Limited

NCT01529320 COMPLETED

Assess Itch Behavior in Nickel Sulphate Sensitized Volunteers

Fundacion IMIM

NCT02241174 WITHDRAWN

0.005% Sodium Hypochlorite Final Rinse Solution in Atopic Dermatitis

Makati Medical Center

NCT02576093 COMPLETED

Safety, Tolerability, Pharmacokinetics and Efficacy of WOL071-007 in Atopic Dermatitis Patients

Dr. August Wolff GmbH & Co. KG Arzneimittel

NCT01614756 COMPLETED

A Two-Part, Phase 1, Single-Dose Study of IL-31 mAb (Anti-Interleukin 31 Monoclonal Antibody); in Healthy Subjects and Adults With Atopic Dermatitis

Bristol-Myers Squibb

NCT02379507 COMPLETED

DEC033 Study Product for Mild to Moderate Eczema An Open-label, Adaptive-design Pilot Study

Medicus Research, LLC

NCT01544348 COMPLETED

A Phase 1, Randomized, Placebo-controlled, Dose-escalation Safety Study of MEDI4212 in Subjects With IgE >= 30 IU/mL

MedImmune LLC

NCT00833079 COMPLETED

Bioequivalence of Two Tacrolimus 0.1% Topical Ointment Formulations in Patients With Atopic Dermatitis

Sun Pharmaceutical Industries, Inc.

NCT01702181 COMPLETED

A Safety Study to Evaluate the Use and Effectiveness of a Topical Ointment to Treat Adults With Atopic Dermatitis

Otsuka Pharmaceutical Development & Commercialization, Inc.

NCT00721331 COMPLETED

A Phase I Study to Assess the Safety and Tolerability of Topical CRx-197 Formulations in Healthy Volunteers

Zalicus

NCT07560618 NOT YET RECRUITING

Obtaining Descriptive Classifications of Pruritus and Assessing Change in Pruritus Over Time in Atopic Dermatitis Patients Using Topical Roflumilast Cream.

Integrative Skin Science and Research

NCT05042258 RECRUITING

Using Dupilumab to Improve Circadian Function, Sleep and Pruritus in Children With Moderate/Severe Atopic Dermatitis

Northwestern University

NCT06116526 RECRUITING

Dupilumab De-escalation in Pediatric Atopic Dermatitis

Johns Hopkins University

NCT07006792 RECRUITING

A Study to See How Well Lebrikizumab Works in Adults and Adolescents With Moderate Atopic Dermatitis (Eczema) and High Itch Burden

Eli Lilly and Company

NCT07487831 NOT YET RECRUITING

The Impact of Salt Intake on Sodium in the Skin and Inflammatory Skin Disease

University of California, San Francisco

NCT07447063 NOT YET RECRUITING

The Impact of Dietary Salt on the Severity of Eczema

University of California, San Francisco

NCT06397781 NOT YET RECRUITING

Effect of S. Aureus Skin Decolonization on Disease Severity in Atopic Dermatitis Patients

Boston Children's Hospital

NCT07438509 NOT YET RECRUITING

Efficacy of Crisaborole 2% Cream Versus Placebo in Mild to Moderate Atopic Eczema

Jinnah Postgraduate Medical Centre

NCT07437534 NOT YET RECRUITING

Comparative Evaluation of the Safety and Effectiveness of Crisaborole Ointment (2%) Versus Tacrolimus Ointment (0.1%) for the Topical Treatment of Atopic Dermatitis

Hayat Abad Medical Complex, Peshawar

NCT05566262 ACTIVE NOT RECRUITING

Bodewell Products for the Treatment of Atopic Dermatitis

University of Alabama at Birmingham

NCT07367932 NOT YET RECRUITING

Comparative Study of Crisaborole vs. Tacrolimus in Atopic Dermatitis

Cairo University

NCT07352566 NOT YET RECRUITING

Utilization of a Microdevice for Psoriasis and Atopic Dermatitis

University of California, San Francisco

NCT05268107 RECRUITING

Ethnic Differences in Mechanisms of Action of Dupilumab

University of Michigan

NCT06004986 RECRUITING

DUPIlumab Dose REDUCtion in Patients With Controlled Atopic Eczema

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

NCT05642208 ACTIVE NOT RECRUITING

Dupilumab Step-down Strategy to Maintain Remission in Adult and Adolescents Patients With Atopic Dermatitis

Nantes University Hospital

NCT06906497 RECRUITING

Lebrikizumab in Moderate-to-severe Atopic Dermatitis

Johann E Gudjonsson MD PhD

NCT06773455 ACTIVE NOT RECRUITING

Tralokinumab for Dupilumab Failures

Psoriasis Treatment Center of Central New Jersey

NCT05858619 RECRUITING

Molecular Signatures of Cutaneous Dupilumab Response

University of California, San Francisco

NCT06465732 NOT YET RECRUITING

Efficacy and Safety of Dupilumab in Combination With Tofacitinib in Moderate to Severe Adult AD Patients

Second Affiliated Hospital, School of Medicine, Zhejiang University

NCT05758532 RECRUITING

Non-specific Effects of a Modified Measles Vaccination Schedule to Prevent Allergy and Unrelated Infection in Children

Laure Pittet, MD-PhD

NCT05285839 RECRUITING

Dupixent and Narrowband UVB for Atopic Dermatitis

Psoriasis Treatment Center of Central New Jersey

NCT05436535 COMPLETED

Longitudinal Endotyping Of Atopic Dermatitis Through Transcriptomic Skin Analysis

National Institute of Allergy and Infectious Diseases (NIAID)

NCT05590585 COMPLETED

Dupilumab in Adolescent and Adult Skin of Color Participants: Open-label Moderate-to-severe Eczema Trial

Regeneron Pharmaceuticals

NCT05696392 TERMINATED

The Purpose of This Study is to Evaluate the Effects of Ruxolitinib Cream on Adults With Atopic Dermatitis Experiencing Sleep Disturbance.

Incyte Corporation

NCT07187089 WITHDRAWN

Study of Growth and Bone Mineral Density in Children With Atopic Dermatitis (AD) Treated With Dupilumab

Regeneron Pharmaceuticals

NCT03293030 COMPLETED

Immunogenetic Profiling of Dupilumab for the Treatment of Atopic Dermatitis

University of California, San Francisco

NCT04447417 COMPLETED

Dupilumab Skin Barrier Function Study in Atopic Dermatitis

Sanofi

NCT04033367 COMPLETED

SAR231893-LPS15497- "Dupilumab Effect on Sleep in AD Patients"

Sanofi

NCT05624112 COMPLETED

Dupilumab Skin BArrier Function and LIpidomics STudy in Atopic Dermatitis in China

Sanofi

NCT05507580 COMPLETED

A Study to Assess Treat-to-Target and Dosing Flexibility of Oral Upadacitinib Tablets in Adult Participants With Moderate to Severe Atopic Dermatitis

AbbVie

NCT05602207 COMPLETED

Effects of Abrocitinib in Subjects With Atopic Dermatitis With an Unsatisfactory Response After Treatment With Dupilumab

Innovaderm Research Inc.

NCT05844618 COMPLETED

Short-Term Efficacy of Triamcinolone Acetonide (Aristocort® C) in Subjects with Atopic Dermatitis

Innovaderm Research Inc.

NCT05200403 TERMINATED

Improvement In Scratch Behavior And Sleep In Patients With Atopic Dermatitis

Boston University

NCT03257215 TERMINATED

Can Vitamin D Treatment Help Treat Moderate to Severe Atopic Dermatitis in Young Children? the D-Vex Pilot Study

Murdoch Childrens Research Institute

NCT05680298 COMPLETED

Dupilumab-pediatric Skin Barrier Function and Lipidomics Study in Patients With Atopic Dermatitis in China

Sanofi

NCT03710044 WITHDRAWN

Investigation of Flare and Remission in Subjects With Atopic Dermatitis

LEO Pharma

NCT03832010 COMPLETED

Steroid-reducing Effects of Crisaborole

Johns Hopkins University

NCT03667014 COMPLETED

The Impact of Dupilumab on Quality of Life in Moderate to Severe Atopic Dermatitis Patients

University of California, San Francisco

NCT04271007 COMPLETED

Comparative Study:Topison (Mometasone Furoate) Versus Two Others Mometasone Furoates

Libbs Farmacêutica LTDA

NCT04358224 COMPLETED

The Utility of Functionally Relevant Signature Genes in Assessing the Clinical Outcomes of Dupilumab Treatment

Jonathan A. Bernstein, MD

NCT04023084 COMPLETED

Response of Children With Atopic Dermatitis (Eczema) to Eucrisa

Ann & Robert H Lurie Children's Hospital of Chicago

NCT04016025 COMPLETED

A Clinical Study of Adherence to Methylprednisolone Aceponate in Different Carriers

Jena University Hospital

NCT00671528 TERMINATED

Safety and Efficacy of Quadriderme® in the Treatment of Impetiginous Eczema (Study P05134AM4)

Organon and Co

NCT03539601 TERMINATED

A Study of Crisaborole Ointment 2%; Crisaborole Vehicle; TCS and TCI in Subjects Aged ≥ 2 Years, With Mild-moderate AD

Pfizer

NCT03389893 TERMINATED

Effect of Dupilumab (Anti-IL4Rα) on the Host-Microbe Interface in Atopic Dermatitis

National Institute of Allergy and Infectious Diseases (NIAID)

NCT03868098 COMPLETED

Different Application Rates of Crisaborole Ointment 2% in Adults With Mild to Moderate Atopic Dermatitis

Innovaderm Research Inc.

NCT04900948 COMPLETED

Prevention of Development of Transcutaneous Sensitization in Children With Atopic Dermatitis During Their First Year of Life

National Medical Research Center for Children's Health, Russian Federation

NCT04114097 COMPLETED

The Effects of Topical Corticosteroid Use on Insulin Sensitivity and Bone Turnover

Jacob Thyssen

NCT03630198 COMPLETED

Pain Outcomes Following Intralesional Corticosteroid Injections

Vanderbilt University Medical Center

NCT02519556 COMPLETED

Trial on Effectiveness Combined Probiotics in Atopic Dermatitis in Children

Casa Espirita Terra de Ismael

NCT03388866 COMPLETED

Effect of Sublingual Immunotherapy in Patients With Atopic Dermatitis

Casa Espirita Terra de Ismael

NCT03050294 COMPLETED

Evaluating Treatment Resistant Dermatitis TaroIIR

Wake Forest University Health Sciences

NCT03356977 COMPLETED

A Study of Crisaborole Ointment 2% in Children Aged 3-24 Months With Mild to Moderate Atopic Dermatitis

Pfizer

NCT02534467 COMPLETED

Does Treatment With Montelukast Improve Symptoms of Atopic Dermatitis in Children?

Murdoch Childrens Research Institute

NCT02300701 COMPLETED

Role of Anti-IgE in Severe Childhood Eczema

Guy's and St Thomas' NHS Foundation Trust

NCT02680301 COMPLETED

Topical Steroid Formulation and Wet Wraps

Seton Healthcare Family

NCT02317276 TERMINATED

A Study to Determine Serum and Skin Biopsy Biomarkers in Patients Receiving Topical Corticosteroid (TCS) and Following TCS Withdrawal

University of California, San Francisco

NCT03406117 COMPLETED

A Study to Determine the Safety and Sensitizing Potential of HAT1 Topical Products Using Skin Sensitivity Patch Tests

Haus Bioceuticals

NCT01093469 COMPLETED

Comparing Aquaphor to Atopiclair and EpiCeram in Children With Mild to Moderate Atopic Dermatitis

Wake Forest University Health Sciences

NCT00654355 COMPLETED

Measuring Adherence to Topical Therapy in Children With Atopic Dermatitis and the Impact of a Return Visit

Wake Forest University

NCT01049243 COMPLETED

A Study Evaluating the Efficacy of Fluocinonide Cream 0.1% (Vanos) in Subjects With Atopic Dermatitis

Wake Forest University Health Sciences

NCT03246776 COMPLETED

Microbial Colonization and Change of Chronic Keratinized Hand Eczema After Using Halometasone Triclosan

Beijing Friendship Hospital

NCT00819507 COMPLETED

VANOS Cream and Skin Barrier Function

Oregon Health and Science University

NCT00828412 COMPLETED

Comparison of the Efficacy and Safety of Two Topical Creams for Pediatric Atopic Dermatitis

Promius Pharma, LLC

NCT02732314 COMPLETED

Efficacy and Tolerability of New Topical Formulations in Subjects With Atopic Dermatitis

Procter & Gamble Beauty

NCT01064947 COMPLETED

Safety and Efficacy Study of Altabax Ointment in the Treatment of Secondarily Infected Atopic Dermatitis

Derm Research, PLLC

NCT01126268 COMPLETED

Twice Daily Altabax Application for the Treatment of Uncomplicated Soft Tissue Infection

The University of Texas Health Science Center, Houston

NCT00871208 WITHDRAWN

Trial of Treatment of Atopic Dermatitis With Concurrent Altabax® and Topical Low-Potency Corticosteroids Versus Low-Potency Corticosteroid Mono-therapy

St. Luke's-Roosevelt Hospital Center

NCT00557284 COMPLETED

Efficacy Study of Montelukast in Atopic Dermatitis Induced by Food Allergens

1st Allergy & Clinical Research Center

NCT00673725 COMPLETED

Locobase® REPAIR Used as an Adjunctive to Standard Therapy in Children With Moderate to Severe Atopic Dermatitis

Astellas Pharma Europe B.V.

NCT01745159 COMPLETED

Preventive Treatment of Tacrolimus Ointment in Children With Atopic Dermatitis

Astellas Pharma China, Inc.

NCT01231854 TERMINATED

Ciclosporin Versus Alitretinoin for Severe Atopic Hand Dermatitis.

Technische Universität Dresden

NCT00884325 COMPLETED

Management of Pruritus With Xyzal in Atopic Dermatitis

Derm Research, PLLC

NCT01065714 COMPLETED

A Study to Investigate the Use of Hydrogel Vehicle in Maintaining the Skin Barrier in Persons With Atopic Dermatitis

Derm Research, PLLC

NCT01782729 COMPLETED

An Efficacy and Safety Study of Tacrolimus Ointment in Pediatric Participants With Atopic Dermatitis

Janssen-Cilag Ltd.,Thailand

NCT01077882 COMPLETED

Analysis of the Quality of Life, the Clinical Effectiveness and Cost-effectiveness of a Novel Educational Programme in Patients With Psoriasis and Atopic Dermatitis

University Hospital, Ghent

NCT01063218 COMPLETED

Evaluation of Cetaphil Advanced Usage to Control Light to Moderate Atopic Dermatitis, in Attempt to Reduce the Necessity of Topic Corticoids Application

Galderma Brasil Ltda.

NCT00878670 COMPLETED

Investigation of Efficacy and Safety of EPOGAM

Max Zeller Soehne AG

NCT01202149 COMPLETED

Bilateral Comparison Study of Elidel 1% and Hylatopic Plus Emollient Foam for the Treatment of Subjects With Atopic Dermatitis

Frankel, Amylynne, M.D.

NCT00832585 COMPLETED

Study to Evaluate the Safety and Efficacy of Alefacept (Amevive) in Subjects With Moderate to Severe Atopic Dermatitis

Rush University Medical Center

NCT01177566 COMPLETED

Pimecrolimus Cream 1% (Elidel®) and Medicated Device Cream (EletoneTM) in the Treatment and Maintenance of Atopic Dermatitis.

Emer, Jason, M.D.

NCT00846235 COMPLETED

Effect of Moisturising Creams on Skin Moisture in Atopic Dermatitis

Orion Corporation, Orion Pharma

Full Atopic Dermatitis Pipeline

Every sponsor, every trial across Phase 1–4. Sortable, filterable, exportable.

Unlock with Pro

Data: ClinicalTrials.gov · Trials registered 2008 onwards · Industry sponsors only